**Review Article**

**Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies**

Angelica Leticia Reis Pavanelli,1 Bruna Silva de Menezes,2 Erica Bianca Barbosa Pereira,2 Fabio Assuncao de Souza Morais,2 Joni Augusto Cirelli,1 and Rafael Scaf de Molon1,2

1Department of Diagnosis and Surgery, São Paulo State University-UNESP, School of Dentistry, Araraquara SP 14801-930, Brazil
2Department of Clinical Dentistry, Federal University of Rio de Janeiro, Rio de Janeiro RJ 21941-617, Brazil

Correspondence should be addressed to Rafael Scaf de Molon; rafael.molon@unesp.br

Received 31 January 2022; Revised 28 March 2022; Accepted 13 April 2022; Published 2 May 2022

Academic Editor: Fu-Ming Tsai

Copyright © 2022 Angelica Leticia Reis Pavanelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Periodontitis, a highly prevalent multicausal chronic inflammatory and destructive disease, develops as a result of complex host-parasite interactions. Dysbiotic bacterial biofilm in contact with the gingival tissues initiates a cascade of inflammatory events, mediated and modulated by the host’s immune response, which is characterized by increased expression of several inflammatory mediators such as cytokines and chemokines in the connective tissue. If periodontal disease (PD) is left untreated, it results in the destruction of the supporting tissues around the teeth, including periodontal ligament, cementum, and alveolar bone, which lead to a wide range of disabilities and poor quality of life, thus imposing significant burdens. This process depends on the differentiation and activity of osteoclasts, the cells responsible for reabsorbing the bone tissue. Therefore, the inhibition of differentiation or activity of these cells is a promising strategy for controlling bone resorption. Several pharmacological drugs that target osteoclasts and inflammatory cells with immunomodulatory and anti-inflammatory effects, such as bisphosphonates, anti-RANK-L antibody, strontium ranelate, cathepsin inhibitors, curcumin, flavonoids, specialized proresolving mediators, and probiotics, were already described to manage inflammatory bone resorption during experimental PD progression in preclinical studies. Meanwhile, a growing number of studies have described the beneficial effects of herbal products in inhibiting bone resorption in experimental PD. Therefore, this review summarizes the role of several pharmacological drugs used for PD prevention and treatment and highlights the targeted action of all those drugs with antiresorptive properties. In addition, our review provides a timely and critical appraisal for the scientific rationale use of the antiresorptive and immunomodulatory medications in preclinical studies, which will help to understand the basis for its clinical application.

1. Introduction

Periodontal disease (PD), a chronic inflammatory condition of the supporting tissues around the teeth, is characterized by the loss of supporting structures of the tooth, such as gingiva, periodontal ligament, alveolar bone, and cementum [1–3]. This condition leads to an irreversible loss of the dental structures and might result in tooth loss if left untreated [1, 4]. The etiology of PD is multifactorial in which the presence of a dysbiotic biofilm in intimate contact with the gingival margin initiates the inflammatory immune response [3, 5, 6]. Indeed, PD is the sixth most prevalent disease globally [7] and is considered the most important cause of tooth loss in the adult population [8].

PD is modulated and mediated by the immune host system, which plays an important role in disease severity and progression [6]. During the initiation and progression of PD, environmental conditions (smoking), systemic comorbidities (diabetes mellitus and rheumatoid arthritis), and genetic polymorphisms (IL-1ß) are important aspects that
dictate the disease progression [9–11]. In the initiation phase of PD, there is an activation of the inflammatory response, which is characterized by increased gingival crevicular fluid, and an influx of inflammatory cells (leukocytes), especially the polymorphonuclear neutrophils (PMN), that tends to diminish the insult caused by the dysbiotic biofilm [4]. All of these events are protective, and in most patients, the immune system is capable of controlling the disease progression. However, innate and adaptive responses in susceptible patients lead to the aggravation of periodontal tissue destruction. The activation of leucocytes and T cells in the connective tissue leads to the production of multiple inflammatory mediators, degrading enzymes such as matrix metalloproteinases (MMP), and the increased expression of the nuclear factor-kappa B ligand (RANKL), which is the primary activation factor for osteoclasts [12], leading to periodontal inflammation and finally causing the loss of bone supporting tissue (Figure 1) [13–15].

The primary treatment of PD is through scaling and root planning (SRP) to remove the attached biofilm from the root surface. However, removing bacterial biofilm does not imply a return to homeostasis and regeneration of lost tissues [16, 17], and SRP targeting only microorganisms does not accomplish favorable results in all patients [18]. Adjunctive treatments such as systemic local antibiotics, nonsteroidal anti-inflammatory drugs, and low doses of doxycycline have been used as host modulating agents in order to control the progression of PD [19–22]. Despite the clinical benefits of those approaches, their effects are limited in the context of inflammation-induced alveolar bone loss [23]. The major challenge for successfully treating PD is the difficulty in finding a target that can inhibit tissue inflammation and consequently alveolar bone destruction [24]. Therefore, the adjunct use of complementary therapies that are aimed at modulating the destructive events of the immune response has been proposed as a potential therapeutic strategy for PD treatment targeting inflammatory mediators and bone-resorbing osteoclasts.

In recent decades, the use of pharmacological drugs and natural compounds (herbal medicine) aiming to suppress bone destruction during experimental PD in animal models has been extensively reported [25–34]. Interestingly, several studies have shown that inhibition of bone loss can be targeted intervened by innumerable pharmacological drugs, such as alendronate [35–38], OPG-Fc [26], resolvin [39–42], strontium ranelate [27, 43], curcumin [17, 31, 44–47], and cathepsin inhibitors [29, 48]. Therefore, in this review, we comprehensively summarize the roles of several therapeutic drugs during the progression of PD and provide the main findings of each included study leading to the prevention of experimental PD.

In this review, the pharmacological products discussed below are examined through many experiments for their antiosteoclastic activity. The in vivo studies included in this
review are based on well-established experimental models of PD, such as ligature-induced bone loss [49–57], lipopolysaccharide (LPS) injections [58–61], and oral inoculation of periodontopathogenic bacteria into the animal mouth [50, 58–60]. Primary methods used to evaluate the inhibition of bone loss were assessed by microcomputed tomography (micro-CT) and histopathological analyses. Oral gavage, palatal injections, and intraperitoneal injections represent the main routes of drug administration in experimental models of periodontitis in rats and mice. Humanized mouse models, subcutaneous bacterial injections, or other animal models were not investigated in this review. We have described the objective, study design, main findings, and conclusions of all the included studies, according to Tables 1–9.

2. Cathepsin K Inhibitors

Cathepsin K (CtsK) is a member of the papain superfamily (C1 protein family) of cysteine protease that plays an important role in the innate immune response and osteoclast-mediated bone resorption [24, 62]. It was previously identified as an osteoclast selective protease CtsK [63] abundantly expressed in human osteoclasts, osteoblasts, periodontal ligament cells, osteocytes, and fibroblasts. In the bone tissue, CtsK can cleave the triple helix and the telopeptides from the type I collagen fibers that constitute 90% of the bone organic matrix [64]. In addition, this protease can also activate MMP-9 [65] and degrade type II collagen [66], osteo- nectin, and osteopontin, thus inhibiting the activity of osteoclasts [64]. It is important to mention that CtsK inhibitors are able to prevent bone resorption without affecting osteoblastic activity. Therefore, the crosstalk between osteoblast and osteoclast is maintained, which is beneficial during bone remodeling [67]. A summary of main study outcomes is described down below (Table 1).

Previous studies have described selective CtsK inhibitors that effectively reduce osteoclast resorption both in vitro and in vivo [68–70]. Furthermore, CtsK has been shown to be an efficient therapeutic strategy in preclinical studies, including inflammatory, metabolic, and autoimmune diseases, such as high fat acid-induced obese mice [71], experimental periodontitis [24, 25, 72], and collagen-induced arthritis (CIA) [72]. However, although CtsK inhibitor has potent inhibitory effects on osteoclast-mediated bone resorption, it has also been associated with some adverse side effects and undesired drug-drug interactions [67, 72, 73]. Odanacatib is an inhibitor of the family member of lysosomal cysteine proteases (cathepsin K inhibitor) involved in the degradation of the demineralized bone matrix; was tested in vitro, in animal models, and in humans; and reached phase III clinical trials [67]. The study was terminated due to an unforeseen increase in cerebrovascular events [74], but...
odanacatib antifracture efficacy encouraged further studies with new cathepsin inhibitors.

Researches have long held that inflammation and bone breakdown are the two major pathological features of periodontitis and rheumatoid arthritis (RA); consequently, prevention or reduction of these damaging events should be a main therapeutic objective. In this regard, Yue et al. [72] recently investigated the efficacy of CtsK inhibition on the course of a combined model of CIA and experimental PD through oral infection with *P. gingivalis*, a known periodontopathogenic bacterium. The results of this study have demonstrated that inhibition of CtsK by transfection of small interfering RNA (siRNA) resulted in diminished destruction of articular tissue and alveolar bone and decreased the macrophage number and inflammatory cytokine expression in the synovium, suggesting that CtsK inhibition might be implicated as a potential therapeutic strategy in experimental PD and RA [72].

Inhibition of CtsK effectively suppresses autoimmune inflammation of the joints as well as osteoclastic bone resorption in autoimmune arthritis [77]. Pan et al. [75] have used an experimental periodontitis model through oral bacterial inoculation combined with CIA in DBA/1J mice. One week before establishing the combined diseases, animals were treated with CtsK inhibitor BML-244. Alveolar bone resorption and paw swelling were more severe when these two comorbidities were present simultaneously. Furthermore, inhibition of CtsK reduced inflammatory cytokine production and infiltration by dendritic cells and T cells. Consequently, bone loss in PD and RA was abrogated as measured by bone erosion in periodontal lesions and cartilage destruction in knee joints. Inhibition of CtsK also decreased the expression of Toll-like receptor (TLR) 4 and TLR9 in vivo [75].

As previously stated, CtsK also has functions in dendritic cells through the TLR9, which plays a pivotal role in innate immunity recognition of microbial products and in the activation of immune host defense [24, 77]. In this context, Hao et al. [24] evaluated whether inhibition of CtsK would benefit both the immune system and bone during the progression of bacterial-induced periodontitis in a mouse model. A small molecular inhibitor, odanacatib, was orally administered one week prior to experimental PD establishment. This study demonstrated that oral application of odanacatib decreased the number of osteoclasts, T cells and macrophages, and TLR, thus preventing bone loss and exacerbated immune response during the progression of PD [24]. Moreover, the same study evidenced that lack of cathepsin K inhibited the expression of toll-like receptors 4, 5, and 9 and their downstream cytokine signaling in the gingival epithelial cell, indicating that the innate immune response was abrogated in periodontitis.

Another study evaluated the inhibition of CtsK through adenoassociated virus (AAV) expressing CtsK small hairpin to silence CtsK [25]. Experimental PD was induced by oral gavage with *P. gingivalis*. AAV-sh-CtsK was administered locally into the palatal gingival tissue. The inhibition of CtsK drastically protected the mice from *P. gingivalis*-induced bone loss (>80%) and significantly reduced inflammation in the gingival tissue. The authors suggested that inhibition of CtsK could target both inflammation and bone resorption and efficiently protect against periodontal bone destruction.

Indeed, the use of CtsK inhibitors for the treatment of osteolytic diseases remains promising. However, in contrast to current antiresorptive agents, which target the osteoclast cells, CtsK inhibitors can cause effects in other tissues, as the enzyme not only is present in bone cells but also engages in several other metabolic processes and regulatory pathways. The challenge, then, is to develop more specific inhibitors, which act on the osteolytic activity of the CtsK, without affecting the activity of other enzyme catalytic sites, decreasing the chance of side effects [67, 78].

CtsK activity is regulated by endogenous cysteine proteinase inhibitors, such as cystatin C, which has a high binding affinity to cysteine proteinases [79]. These proteins are capable of inhibiting osteoclastogenesis and bone resorption in vitro and in an ex vivo model [80, 81]. Recently, our

### Table 2: Bisphosphonates.

| Studies                        | Study design                                                                 | Main outcomes                                                                 |
|-------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Brunsvold et al. (1992) [94]   | Animals: 27 adult cynomolgus monkeys with intact dentitions                  | Decreased the progression of PD as measured by changes in bone density.      |
|                               | Disease model: PD induced by ligature placed around the lower premolars       | Reduced the activity of osteoclasts and the resorption of the alveolar bone.  |
|                               | and molars, plus oral inoculation of *P. gingivalis*. Treatment: alendronate (0.05 mg/kg) for 16 weeks | After 21 days of treatment, some animals developed signs of ONJ due to reduced osteoclast activity. |
|                               | Animals: thirty-six 3-month-old Wistar rats                                 |                                                                              |
|                               | Disease model: ligature-induced PD around the upper right second molar       | The combination of the two treatments showed less local inflammation and enhanced tissue repair. |
|                               | Treatment: daily injections of 2.5 mg/kg body weight alendronate for 7 days before and 7, 14, and 21 days after PD induction. |                                                                              |
| Moreira et al. (2014) [36]    | Animals: ninety 3-month-old Wistar rats                                      |                                                                              |
|                               | Disease model: ligature-induced PD around the lower left first molar         |                                                                              |
|                               | Treatment: scaling and root planning and/or administration of alendronate (irrigation with 1 ml of 10^{-5} M) for 7, 15, and 30 days |                                                                              |
| De Almeida et al. (2015) [35] |                                                                              |                                                                              |
group demonstrated that natural inhibitors of cysteine peptidase derived from Citrus sinensis, named phytocystatin CsinCPI-2, was effective in decreasing the gene expression levels of cathepsin K, cathepsin B, IL-1β, and TNF-α. In addition, CsinCPI-2 significantly inhibited in vivo the activity of TNF-α in the blood of rats, previously stimulated by E. coli lipopolysaccharide (LPS). These data suggested that CsinCPI-2 has a potential anti-inflammatory effect during bacterial infection in rats [82]. Moreover, we have just showed the positive effects of phytocystatin CsinCPI-2 in the inhibition of bone loss in a mouse model of ligature-induced alveolar bone loss. In this study, it was demonstrated that systemic treatment with CsinCPI-2 significantly reduced inflammatory cell infiltrate, decreased the number of TRAP+ cells, and diminished alveolar bone destruction caused by PD. This treatment also showed downregulation of inflammatory cells expressing CD3, CD45, and MAC387 in the connective tissue. Furthermore, in vitro data demonstrated that CsinCPI-2 inhibited RANKL-induced TRAP+ osteoclast formation in BMM and abrogated RANKL-induced mRNA expression of Acp5, Calcr, Ctsk, and RANKL-induced upregulation of Nfatc1 [76].

### Table 3: OPG-Fc and RANKL inhibitors.

| Studies            | Study design                                                                 | Main outcomes                                                                 |
|--------------------|-----------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Teng et al. (2000) | Animals: 8-9-week-old female mice; Disease model: oral inoculation infection with *A. actinomycetemcomitans*; Treatment: intraperitoneal injections every other day with PBS or OPG-Fc (1 mg/kg) between weeks 4 and 8 | Reduced alveolar bone loss, decrease in the number of osteoclasts              |
| Mahamed et al. (2005) | Animals: 200 NOD mice and 18 BALB/c mice; Disease model: NOD mice were injected with STZ to induce hyperglycemia (40-50 mg/kg); Oral inoculation of *A. actinomycetemcomitans* (10 μg/ml); Treatment: intraperitoneal injections with 2.5 μg hu-OPG-Fc/100 μl PBS, 3 times a week for 8 weeks | Treatment of diabetic mice with OPG leads to the inhibition of bone resorption and reduced RANKL expression, and, therefore, OPG may hold therapeutic potential for treatment bone loss in inflammatory conditions |
| Jin et al. (2007) | Animals: 32 male Sprague-Dawley rats; Disease model: ligature-induced PD placed bilaterally between the lower first molars; Treatment: human OPG-Fc (10 mg/kg) or vehicle by subcutaneous injection twice weekly for 6 weeks | OPG-Fc suppressed the number of osteoclasts in the alveolar crest. Preservation of alveolar bone volume |
| Kuritani et al. (2018) | Animals: 8-week-old male C57BL/6j mice; Disease model: LPS-induced calvarial bone destruction. Model of experimental PD using ligatures; Treatment: administration of saline solution, anti-RANKL antibodies (3 mg/kg), or zoledronate (0.2 mg/kg). | Anti-RANKL antibodies significantly inhibited alveolar bone destruction and tooth root exposure. Zoledronate suppressed alveolar bone destruction |

### Table 4: Strontium ranelate (SR).

| Studies            | Study design                                                                 | Main outcomes                                                                 |
|--------------------|-----------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Marie et al. (1993) | Animals: 112 3-month-old Sprague-Dawley female rats; Disease model: estrogen deficiency-induced bone loss; Treatment: 17 beta-estradiol (10 μg/kg/day, sc) or divalent strontium by gavage at a dose of 77, 154, or 308 mg/kg/day or vehicle for 60 days; Animals: 40 Wistar rats | Prevented bone loss and increased trabecular bone volume                       |
| Karakan et al. (2017) | Animals: 48 male Wistar rats; Disease model: ligature-induced experimental PD placed around the first molars in the right mandible; Treatment: strontium in dosages: 300, 625, and 900 mg/kg. Administration by oral gavage for 11 days | Less alveolar bone loss, reduced number of osteoclasts, and increased number of osteoblast cells. Best results at a dosage of 900 mg/kg |
| Souza et al. (2018) | Animals: 96 female Wistar rats ovariecotomized; Disease model: ligature-induced PD placed around the upper molars; Treatment: oral administration of strontium ranelate (20 or 100 mg/kg) for 7 days | Prevented bone resorption and increased heme oxygenase-1 mRNA levels in gingival tissues |
| Martins et al. (2020) | Animals: 96 female Wistar rats ovariecotomized; Disease model: ligature-induced PD in the mandibular first molar for 10, 20, and 30 days | Inhibited bone loss, increased the area of trabecular bone, affected the expression of bone markers |
3. Bisphosphonates

Bisphosphonates, particularly nitrogen-containing ones, such as zoledronate and alendronate, are antiresorptive agents commonly used to treat bone metabolic diseases such as osteoporosis and bone neoplasia, Paget disease, and multiple myeloma. Bisphosphonates inhibit function–such as osteoporosis and bone neoplasia, Paget disease, agents commonly used to treat bone metabolic diseases such as zoledronate and alendronate, are antiresorptive. Bisphosphonates, particularly nitrogen-containing ones,

### Table 5: Anti-IL-6 and anti-TNF-α.

| Studies                  | Study design                                                                 | Main outcomes                                                                 |
|--------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Apolinario Vieira et al. (2021) [114] | Disease model: PD induced by cotton ligature placed on the right first molar in the mandible Treatment: systemic administration of tocilizumab (TCZ) intraperitoneally at concentration dosages (2 mg/kg, 4 mg/kg, and 8 mg/kg) for 7 and 14 days Animals: 80 4-week-old obese diabetic male Zucker rats | Inhibited alveolar bone resorption and attachment loss, lower expression of inflammatory infiltrate and lower production of Th17 and RANKL-related cytokines. |
| Grauballe et al. (2015) [115] | Disease model: PD induced by ligature placement around the maxillary second molars Treatment: anti-TNF-α Etanercept injections for 5 weeks Animals: 52 4-week-old male Zucker rats Disease model: 45 obese rats with type II diabetes and 17 lean rats as controls. PD induced by ligatures around the maxillary second molars | Blocking TNF-α improves metabolic state in obese rats with PD and diminishes periodontal tissue destruction associated with diabetes Anti-TNF-α treatment has a positive impact on the subgingival microbial profile in rats with diabetes and ligature-induced bone loss Decreased expression of TNF-α and increased the expression of IL-10 in the maxilla of mice. It did not affect the expression of IFN-γ and IL-17. Decreased joint inflammation Reduced radiographic bone loss |
| Oates et al. (2002) [113] | Disease model: mice underwent antigen-induced arthritis (AIA) Treatment: intraperitoneal administration of pentoxifylline (50 mg/kg) daily for 14 days Animals: 6 Macaca fascicularis from 3 to 7 years old Disease model: PD induced by silk ligatures inoculated with P. gingivalis in lower premolars, first and second molars Treatment: intrapapillary injections of soluble receptors (blockers), IL-1 and TNF-α (6.6 mg), 3 times a week for 6 weeks | Inhibited alveolar bone resorption and attachment loss, lower expression of inflammatory infiltrate and lower production of Th17 and RANKL-related cytokines. |

Despite its beneficial effects in inhibiting bone resorption in osteolytic diseases, the use of bisphosphonates, especially intravenous administration of high doses of zoledronate, is associated with adverse side effects. The most significant effect associated with bisphosphonate administration is the osteonecrosis of the jaw (ONJ), a condition defined as an area of exposed bone in the maxillofacial region that does not heal after 8 weeks in patients receiving antiresorptive therapies [86, 87]. Furthermore, atypical fractures are also related to the long-term use of bisphosphonate due to its high maintenance of the drug into the bone tissue. On the other hand, the oral administration of alendronate to treat osteoporosis has shown to have a 0% to 0.4% chance of inducing ONJ [88]. Consequently, several studies have investigated the beneficial effects of alendronate administration to manage experimental periodontitis in rats [35, 37, 89, 90] and PD in clinical trials [91–93]. Some of the described studies are described in table 2.

One of the first studies that have used alendronate as adjunctive therapy to manage experimental PD was conducted by Brunsvold et al. in 1992 [94]. In this study, the authors have induced experimental PD in monkeys by placing a ligature around the mandibular premolars and molars followed by oral inoculation of P. gingivalis one week after alendronate administration. Alendronate was administered intravenously for 16 weeks, and clinical and radiographical analyses were performed. The authors demonstrated that 0.05 mg/kg alendronate treatment reduced the progression of PD, suggesting its use to treat PD. Similarly, Moreira et al. [36] have shown that 2.5 mg/kg alendronate administration in rats with experimental PD reduced the activity of osteoclasts and significantly decreased the resorption of the alveolar bone crest. However, after 21 days of treatment, some animals developed signs of ONJ due to the reduced activity of osteoclast. The authors pointed out that using alendronate to treat experimental PD in rats might increase the risk of ONJ development.
The use of alendronate as adjunctive to scaling and root planning (SRP) in rats with induced PD was evaluated by De Almeida et al. [35]. Rats with ligature-induced PD received SRP after ligature removal associated with topical application of alendronate. The animals assigned to receive SRP plus alendronate showed less local inflammation and better tissue repair, associated with higher expression of osteoprotegerin (OPG) immunolabeling, suggesting that the treatment employed might be effective in the treatment of PD in rats. A recent systematic review investigated the potential use of bisphosphonate as an adjuvant to SRP in 13 clinical trials [95]. The results of this systematic literature review demonstrated that locally or systemically administered alendronate reduced probing pocket depth and resulted in a gain of clinical attachment level and improved radiographic assessment. Indeed, bisphosphonate as an adjuvant to SRP may result in clinical benefits in patients with PD. However, the risk to ONJ development after bisphosphonate administration limits their clinical use.

### 4. OPG-Fc and RANKL Inhibitors

The discovery of the RANK, RANK ligand (RANKL), and OPG axis has revealed its pivotal role in regulating bone metabolism and created a new field for the study of bone-related diseases [12]. Binding of RANK to RANKL results in the differentiation and maturation of osteoclast precursor cells to activated osteoclasts. Therefore, blocking the interaction between RANK and RANKL is accountable for inhibiting osteoclast differentiation, and it is considered an interesting alternative to inhibit bone loss in osteolytic lesions. Acting as a soluble decoy receptor for RANKL,
Table 7: Flavonoids.

| Studies             | Study design                                          | Main outcomes                                                                 |
|---------------------|-------------------------------------------------------|-------------------------------------------------------------------------------|
| Lektemur Alpan et al. (2020) [142] | Disease model: PD induced by ligatures in the lower first molars. Treatment: Administration by oral gavage of taxifolin at doses: 1 mg/kg and 10 mg/kg for 29 days. Animals: 32 male Wistar rats. | Reduced alveolar bone loss. High BMP-2, OCN, ALP, and Col 1 expression and lower RANKL immunoexpression |
| Tominari et al. (2012) [145] | Disease model: LPS-induced bone loss (25 μg) on days 0, 2, and 4 for 7 days. Animals: 6-week-old male mice. Treatment: flavonoids—nobiletin or tangeritin (30 μM) for 7 days. | Both flavonoids suppressed osteoclast formation and bone resorption. Decreased osteoclastogenesis in RAW264.7 macrophages |
| Gugliandolo et al. (2019) [140] | Disease model: PD induced by LPS injection (10 μg/ml) in the gingival tissue between the first and second molars. Treatment: bergamot juice flavonoids, 20 mg/kg administered by oral gavage for 14 days. Animals: 40 male Sprague-Dawley rats. | Flavonoid improved the inflammatory process in the gingival tissues. Decreased NF-kB activation and proinflammatory cytokine levels |
| Huang et al. (2016) [141] | Disease model: ligature-induced PD in maxillary molars. Treatment: intraperitoneal injections of low- or high-dose myristicin (2 or 5 mg) every other day for 30 days. Animals: 24 8-week-old ovariectomized female C57BL/6 mice. | In vivo, it suppressed bone loss and increased alveolar crest height |
| Cheng et al. (2010) [138] | Disease model: ligature-induced PD in the molars of the maxilla and mandible. Treatment: quercetin (75 mg/kg) for 5 days. LPS (5 mg/ml) and quercetin plus LPS. Animals: 6-week-old male Sprague-Dawley rats. | In vitro, it inhibited osteoclast formation and bone resorption |
| Carvalho et al. (2021) [137] | Disease model: PD induced by microinjections of LPS on the palatal surface of both first molars. Treatment: food supplement of eriocitrin and eriodictyol (25 and 50 mg) for 30 days. Animals: 60 BALB/c 4-week-old male mice. | Decreased alveolar bone loss and reduced inflammatory cell infiltrate in connective tissue |
| Kuo et al. (2019) [34] | Disease model: ligature-induced PD in the upper and lower first second molars. Treatment: hesperidin at doses 75 or 150 mg/kg by intragastric gavage for 7 days. Animals: 48 male rats. | Decreased LPS-induced osteoclast formation in vitro |
| Balci Yuce et al. (2019) [32] | Disease model: ligature-induced PD around the lower right first molars. Treatment: luteolin 50 mg or 100 mg given by oral gavage for 11 days. Animals: 28 male Wistar rats. | Inhibited periodontal inflammation |
| Taskan et al. (2019) [135] | Disease model: ligature-induced PD in the lower right first molar. Treatment: administration by oral gavage of oleuropein 12 or 25 mg/kg for 14 days. Animals: 32 female Wistar rats. | Inhibited alveolar bone loss and the production of proinflammatory mediators |
|                     |                                                       | Decreased bone loss in both groups. Greater number of osteoblast cells and decreased number of inflammatory cells |
|                     |                                                       | Decreased alveolar bone loss due to decreased osteoclastic activity, inflammation, and apoptosis and increased osteoblastic activity |

OPG binds to RANKL and inhibits osteoclast development preventing it from binding to RANK. OPG has been evaluated in preclinical studies of experimental PD as a therapeutic compound for counteracting bone loss (Figure 2). The pioneering study that has used OPG to treat experimental PD was performed by Teng et al. [96]. Using an oral inoculation infection model with *A. actinomycetemcomitans* in mice, the authors demonstrated that in vivo inhibition of RANKL function with OPG treatment reduces alveolar bone loss and decreases the number of osteoclasts after microbial challenge. These data imply that OPG treatment may thus have therapeutic value to prevent alveolar bone and/or tooth loss in human periodontitis. In this context, Mahamed et al. [97] showed diminished alveolar bone resorption in diabetic mice treated with the RANKL antagonist OPG, which is in agreement with the study of Teng et al. [96]. Using an acute model of ligature-induced bone loss, Jin et al. [26] demonstrated protective effects of OPG-Fc during experimental PD with significant preservation of alveolar bone. Therefore, OPG revealed robust preventive effects on alveolar bone resorption in experimental PD, thus showing a promising therapeutic potential of OPG for PD treatment.

Moreover, an anti-RANKL monoclonal antibody denosumab has been developed and used to treat bone metabolic diseases such as osteoporosis and metastatic bone cancers and other osteolytic bone conditions such as periodontitis and arthritis. Denosumab binds directly to the RANKL to prevent its interaction with RANK...
on osteoclasts. This binding inhibits osteoclast formation, differentiation, and function [85], thus inhibiting bone resorption. Denosumab does not bind to mouse RANKL; therefore, studies have used an anti-mouse monoclonal RANKL to investigate its potential effects on mice. In this context, Kuritani et al. [98] investigated the effects of systemic administration of anti-RANKL during the progression of ligature-induced bone loss in mice. The study findings showed that anti-RANKL antibody strongly suppressed alveolar bone loss associated with periodontitis. However, similar to bisphosphonates, the potential risk of development of medication-related osteonecrosis of the jaw [99–102] and the use of denosumab or RANKL inhibitors as an adjunctive treatment for PD are not indicated. Table 3 describes the main study outcomes with RANKL inhibitors.

5. Strontium Ranelate (SR)

SR, an antiresorptive compound mainly used for osteoporosis treatment, is a silver-white and soft metallic chemical element. It is placed primarily in areas where mineralization of new bone occurs, such as regions experiencing intramembranous or endochondral ossification [103]. SR is known as a divalent cation that has atomic and ionic properties related to calcium and is also considered as a dual-acting agent that diminishes bone resorption by decreasing osteoclastic activity and stimulating bone formation by proliferation of preosteoblast and secondarily increasing the activity of functional cells and synthesis of bone matrix [104, 105]. This dual-acting mechanism of SR (concomitant antiresorptive and osteoanabolic dual biological activity) represents an advantage over bisphosphonates. Thus, SR is able to increase biomechanical and structural properties of bone, such as mineral density [106]. There are two possible mechanisms of action presented in literature about SR: (1) activating calcium-sensing receptor or another cation-sensing receptor and (2) increasing expression of OPG in addition to decreasing RANKL expression by osteoblasts [107].

One of the first studies investigating the efficacy of SR in preventing bone resorption was made by Marie et al. [108]. This study tested low SR doses on bone loss induced by estrogen deficiency in female rats. Treatment for 60 days with SR resulted in a dose-dependent increase in plasma, urine, and bone strontium concentrations without any deleterious effect on total or skeletal growth. Furthermore, treatment of OVX rats with SR prevented bone loss and bone mineral content was restored to the values in sham rats. Moreover, SR treatment increased the trabecular bone volume up to 30%. On the other hand, two other studies showed that SR administration did not counteract the loss in bone architecture and bone strength in ovariectomized rats [109, 110]. These contradictory findings lead to a deeper investigation of the potential role of SR in other inflammatory diseases such as PD.

In this context, Karakan et al. [27] investigated the effects of SR administration in rats with ligature-induced PD. Three different dosages of SR were used: 300, 625, and 900 mg/kg, and the administration was performed daily by oral gavage. The rats were euthanized 11 days after ligature placement. The results indicated that SR leads to decreased bone loss and reduced osteoclast number. In addition, the number of osteoblast cells was significantly increased after SR treatment. Collectively, the findings of this study suggested that SR at 900 mg/kg might prevent alveolar bone loss in this animal model. Another study conducted by Souza et al. [111] has determined the effect of SR on ligature-induced bone loss in rats. The authors showed that SR prevented periodontal bone loss with concomitant upregulation of heme oxygenase 1 mRNA levels. A recent study also demonstrated the beneficial effects of SR on alveolar bone loss in rats with concomitant PD and estrogen deficiency [43]. The
Biological therapies include a range of anticytokine agents, including anti-TNF-α, anti-IL-6, anti-IL-1, and T and B cells. These specific agents are monoclonal antibodies that act blocking the activity of cytokines and thus inhibiting the immune-inflammatory response of the host, functioning as an immune suppressant [18]. The use of biological agents to manage experimental PD in animal models has demonstrated potential efficacy for anticytokine therapies in ameliorating bone destruction and reducing inflammatory cell infiltrate [112–114], as described below (Table 5).

6. Biological Therapies

Biological therapies are a novel class of compounds mainly used to treat autoimmune diseases such as rheumatoid arthritis and other chronic inflammatory conditions, i.e., Crohn’s disease, ankylosing spondylitis, and ulcerative colitis [18]. Biological therapies include a range of anticytokine

| Studies           | Study design                                                                                           | Main outcomes                                                                                     |
|-------------------|--------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Moraes et al. (2020) [166] | Disease model: ligature-induced PD; ligature and live L. reuteri; treatment: live or dead L. reuteri given orally 30 days before the disease and 14 days after | Increased alveolar bone volume and trabecular number                                                   |
| Cardoso et al. (2020) [167] | Disease model: ligature-induced PD and CIA arthritis model treatment: probiotic (HN019) supplied to animals (1.5 × 10⁶ CFU/ml) for 39 days | Reduced alveolar bone loss and TNF-α and IL-6 levels and increased IL-17 levels. Decreased levels of ACPA antibodies |
| Ricoldi et al. (2017) [168] | Disease model: ligature-induced PD around the lower right first molars treatment: 10 ml of 10% skim milk with B. lactis HN019 once daily for 15 days | Reduced alveolar bone resorption and attachment loss. Increased expression of anti-inflammatory cytokines and reduced expression of proinflammatory cytokines |
| Oliveira et al. (2017) [169] | Disease model: PD induced by cotton ligatures around the lower first molars treatment: Probiotic HN019 administered topically to the subgingival region of molars on days 0, 3, and 7 | Less alveolar bone resorption and attachment loss                                                     |
| Gatej et al. (2018) [170] | Disease model: PD was induced by oral inoculation with P. gingivalis treatment: probiotic Lactobacillus rhamnosus was given by oral gavage before and during disease induction | Reduced bone loss and gingival inflammation                                                          |
| Maekawa and Hajishengallis (2014) [171] | Disease model: ligature-induced PD around the upper left second molar treatment: L. brevis CD2 applied topically between the gingiva and the buccal mucosa | Decreased bone loss and lower expression of TNF, IL-1β, IL-6, and IL-17A                             |
| Kobayashi et al. (2017) [172] | Disease model: PD induced by injection of P. gingivalis in the mandibular molars treatment: Lactobacillus gasseri SBT2055 (LG2055) given by gavage daily for 5 weeks | Reduced alveolar bone loss and decreased TNF-α and IL-6 expression in the gingival tissue              |
| Levi et al. (2018) [173] | Disease model: ligature-induced PD treatment: Mannanoligosaccharide (MOS) added daily to the food for 30 days prior to PD | Decreased alveolar bone loss and increased bone mineral density. Decreased expression of IL-10 and IFN-γ and TNF-α genes |

results indicated that SR prevented ligature-induced bone loss in an estrogen-deficiency condition and, to a certain extent, increased trabecular bone area in the presence and absence of periodontal collapse. Furthermore, SR also decreased the expression levels of bone markers, such as RANKL and osteocalcin, appearing to have acted predominantly as an antiresorptive agent. Taken together, the results of these investigations demonstrated that SR plays an important role in inhibiting bone loss in experimental PD (Table 4).
decreased after treatment. The authors suggested that modulatory therapy with biological agents might be an interesting alternative to inhibit alveolar bone loss, and further studies are warranted to confirm the data.

6.3. Anti-TNF-α. Tumor necrosis factor-alpha is a key signaling modulator in the pathogenesis of PD, and its upregulation is associated with increased osteoclastogenesis. Thus, investigations targeting TNF-α have been evaluated to manage inflammatory bone resorption in animal models. In this context, a recent study evaluated the effects of systemic administration of Etanercept in mice with concomitant diabetes mellitus and periodontitis [115]. Obese diabetic Zucker rats were systemically administered with Etanercept and one week later received ligature to induce experimental PD. Animals were sacrificed after 5 weeks from the baseline. This study indicates that blocking TNF-α improves the metabolic status in obese rats with PD and decreases periodontal breakdown associated with diabetes. The same research group also confirmed that anti-TNF-α treatment positively impacts the subgingival microbial profile in rats with diabetes and ligature-induced bone loss [116]. Another study investigated anti-TNF-α effects with pentoxifylline in an experimental mouse model of chronic antigen-induced arthritis- (AIA-) associated PD [117]. The authors demonstrated that the treatment employed was able to diminish joint inflammation, reduce the levels of TNF-α and IL-17, and prevent signs of PD (decreased the number of osteoclasts and recruitment of neutrophils in the connective tissue). In addition, the treatment employed showed the anti-inflammatory and bone protective effects in mice with AIA and concomitant PD. Accordingly, a previous study also demonstrated the positive effects of anti-TNF-α on the progression of experimental PD induced by ligature placement by decreasing radiographical bone loss [113]. Finally, Cirelli et al. have used adenoassociated virus vector based on serotype 1 (AAV2/1) to deliver the TNF receptor-immunoglobulin Fc (TNFR:Fc) fusion gene to rats subjected to experimental periodontitis by means of P. gingivalis LPS-mediated bone loss [118]. The results showed that AAV2/1-TNFR:Fc administration diminished the levels of several pro-inflammatory cytokines and osteoclast-like cells in the connective tissue of rats. These data indicate that delivery of AAV2/1-TNFR:Fc might be a feasible approach to modulate PD progression.

7. Herbal Medicine

7.1. Curcumin. Curcumin is a bioactive compound of turmeric and derived from Curcuma longa, a tropical plant
native to Southeast Asia [119]. It is a yellow hydrophobic polyphenol composed of three curcuminoids, and it is largely used in dietary spice. It has been reported that curcumin has a variety of biological activities, including osteoimmune modulatory properties and anti-inflammatory, antioxidant, antiangiogenic, and antibacterial effects with the capacity to modulate the innate immune host response [31, 46, 120–123]. Due to the innumerable beneficial effects described in the literature with the use of curcumin to treat experimental PD, natural or chemically modified curcumin has been suggested as an interesting therapeutic approach to managing inflammatory bone resorption [30, 31, 45, 46, 120–123]. Nevertheless, different variables, such as diverse dosages (in vitro and in vivo), vehicle used, and administration route (intraperitoneally, intravenously, and orally), have also been described in the literature [30, 31, 46, 121, 123, 124].

Many investigations have been carried out to evaluate curcumin effects during the progression of experimental PD in murine [30, 31, 45, 46, 120–124] (Table 6). Recently, Pimentel et al. [125] assessed the impact of curcumin (100 mg/kg) on the progression of experimental PD in diabetic rats. The PD model was induced by placing cotton ligatures around the first mandibular molar and in the second maxillary molar. An injection of streptozotocin was intraperitoneally administered in the animals to induce experimental diabetes. Curcumin was administered daily by oral gavage for 30 days. The results indicated that natural curcumin reduces alveolar bone loss and favorably modulates the osteoimmune inflammatory process during disease progression. Interestingly, Zambrano et al. [31] investigate the local administration of curcumin-loaded nanoparticles in an experimental PD model. A model of Escherichia coli bacterial lipopolysaccharide (LPS) injection was used to induce PD. The curcumin nanoparticles were locally injected, 2 times per week for four weeks, in the palatal mucosa around the first maxillary molar. Radiographical analysis (micro-CT) showed significant reduction in the loss of alveolar bone caused by LPS in the animals treated with curcumin nanoparticles. A previous study [126] using the silk ligation model of PD in rats demonstrated the potent capacity of oral administration of curcumin (100 mg/kg/day) for 30 days to inhibit bone resorption, which is in agreement with the above-reported studies [31, 125].

Previous studies have used different strategies to enhance the clinical application of curcumin to treat experimental PD. Indeed, chemically modified compounds have been developed to increase their clinical efficacy, which resulted in greater bioavailability maintaining its biological and safety properties [46, 120, 121, 128], de Almeida Brandao et al. [120] evaluated the effects of a modified curcumin so-called CMC2.24 that is a novel bis-dimethoxy-4-phenylaminocarbonyl curcuminoid. In this study, rats underwent experimental PD using direct microinjections of Escherichia coli bacterial LPS into the gingival tissue around the first maxillary molars three times per week. Curcumin was administered daily by oral gavage immediately after LPS injection and continued for the whole experimental period of 28 days. The outcomes showed that CMC2.24 inhibited bone loss, inflammation, and osteoclastogenesis in the LPS-induced periodontitis model even at a low dosage (1 mg/kg/day), suggesting that this compound is more effective than previously documented. Curylofo-Zotti et al. [46] also investigated the effects of CMC2.24 in a model of LPS-induced PD. Similar to the study mentioned above [120], the authors showed that oral administration of curcumin CMC2.24 (30 mg/kg/day) significantly inhibited inflammatory infiltrate in the gingival tissue, decreased the number of osteoclasts, and abrogates bone resorption, pointing to an interesting potential of CMC2.24 in preventing bone resorption in an inflammatory model of PD. Similarly, Elburki et al. [127] showed that oral gavage with CMC2.24 (30 mg/kg/day) also reduced inflammation-mediated connective tissue breakdown in rats with diabetes (induced by intravenous injection of streptozotocin) and PD (induced by E. coli LPS injections) and prevented hyperglycemia-induced tissue destruction. CMC2.24 was also able to attenuate the severity of inflammation and bone loss in the periodontal tissues, acting as a potential therapeutic inhibitor of bone resorption in inflammatory conditions. These findings parallel previous observations by the same research group [121] that demonstrated the positive effects of CMC2.24 in inhibiting bone resorption during LPS-induced experimental PD in rats.

Taken together, several studies have demonstrated the beneficial effects of natural curcumin or chemically modified curcumin to treat experimental PD without adverse side effects. Nevertheless, it is important to bear in mind that the differences in dosages used in the studies, the low absorption rate, reduced half-life, and rapid systemic elimination [129] might limit its clinical use to treat PD in humans.

7.2. Chalcones. Chalcone is a medicinal plant that has been conventionally used in Brazilian medicine to treat bleeding gums [130]. It is a phenolic compound extracted from the Myrrhodruon urundeuva (Engl.). This compound presents analgesic and anti-inflammatory properties as evidenced by previous studies in experimental models of inflammation [130, 131]. Moreover, antioxidant, antimicrobial, and antiresorptive properties were previously described during inflammatory conditions, including RA and inflammatory bowel diseases [132, 133]. Therefore, based on the assumption that chalcone presents beneficial properties in inflammation, previous studies have investigated its potential therapeutic effects during experimental periodontitis in rats.

In a study of ligature-induced periodontal bone loss in rats, Botelho et al. [134] assessed the effects of a gel containing chalcones during the progression of PD. Rats underwent nylon ligature placement around the second maxillary molars and received immediately after its placement the chalcone gel (600 μg/g gel) topicaly applied to the gingival tissues three times per day during the entire experimental period (11 days). The results showed that chalcone gel prevents alveolar bone resorption in the conditions studied and presented with anti-inflammatory and antimicrobial effects during the course of PD.

More recently, Fernandes et al. [47] evaluated the effects of chalcone T4 during the progression of experimental PD.
In this study, PD was induced by placing a cotton ligature around the first mandibular molar. Chalcone T4 was systemically administered daily by intragastric gavage (5 and 50 mg/kg) starting on the same day of ligature placement. After 15 days of treatment, the animals were sacrificed, and measurements of radiographical, histological, and molecular analyses were performed. The data indicate that 5 mg/kg of chalcone T4 decreased bone resorption and cellular infiltrate in the connective tissue. Moreover, in vitro data demonstrated that this treatment resulted in a reduced number of osteoclasts and resorption area in raw 267.4 cells. As a proof-of-concept study, the data suggested the potential effect of chalcone T4 as an adjuvant for experimental PD treatment. More studies are warranted to investigate dose response, the effects in different inflammatory models, and the factors that might influence its bioavailability, to better comprehend the pharmacokinetics and pharmacodynamic behavior of chalcone T4 [47].

7.3. Flavonoids. In an attempt to pursue natural products with pharmacokinetic, anti-inflammatory, antioxidant, and immunomodulatory effects, growing attention has been dedicated to searching phenolic compounds that might have protective effects on bone and connective tissue [135]. Flavonoids, a group of polyphenolic compounds found in many plants (soybean, olive), fruits (orange peel), vegetables, seeds and beverages, have been suggested as a possible alternative to treat inflammatory bone resorption due to its wide range of biological properties and activities [136]. Therefore, the dietary intake of natural ingredients, including innumerable flavonoids, might be beneficial for bone tissues and can prevent PD progression and severity in different animal models of periodontitis. In this context, many studies have used different types of flavonoids to prevent and treat experimental periodontitis with beneficial effects on the alveolar bone tissue without adverse effects [32–34, 135, 137–142].

Genistein, an isoflavone found in soybean, attenuates alveolar bone loss in a rat model of ligature-induced periodontitis [139]. It has also been reported that genistein inhibits bone loss in ovariectomized (OVX) mice, pointing to an important role in preventing experimental postmenopausal osteoporosis [143]. Taxifolin is a flavanone with potent antioxidant properties that has been shown to stimulate osteoblast differentiation and suppress osteoclastogenesis in vitro [144]. Recently, Lektemur Alpan et al. [142] demonstrated that taxifolin attenuates inflammatory bone resorption in a model of ligature-induced bone loss in rats, decreases inflammatory infiltrate, and improves alveolar bone formation. In an experimental model of LPS-induced inflammatory bone loss, the administration of the flavonoids nobiletin and tangeretin was able to suppress LPS-induced osteoclast formation and bone loss. Furthermore, both flavonoids inhibited osteoclastogenesis in RAW264.7 macrophages [145]. Similarly, the effect of a flavonoid from the bergamot juice could inhibit bone loss and decrease gingival inflammation markers in a rat model of LPS-induced PD [140]. Huang et al. [141] evaluated the effects of myricetin, a naturally occurring flavonoid compound, in an experimental OVX mouse PD model. Systemic administration of myricetin prevented bone loss and enhanced alveolar crest height in vivo, and attenuated osteoclast formation and bone resorption in vitro [141] (Table 7).

Quercetin is an abundant flavonol-type flavonoid that has been associated with innumerable beneficial effects regarding the inflammatory process and immune functions [146–148]. The effects of quercetin on the progression of experimental PD were evaluated by Cheng et al. [138]. Utilizing a model of ligature-induced bone loss, the authors demonstrated decreased alveolar bone loss and reduced inflammatory cell infiltrate in the connective tissue of rats that have received systemic administration of quercetin. Moreover, in vitro data demonstrated that quercetin diminished LPS-induced osteoclast formation, suggesting that it might possess an ameliorative effect during PD progression [138]. Recently, it was demonstrated that a citrus flavonoid—eriocitrin and eriodictyol—diminished inflammatory cell infiltration in the connective tissue of rats with induced PD by means of LPS-injections suggesting that a diet supplemented with flavonoids might enhance local immunity and host defense [137]. Finally, other studies showed beneficial effects of hesperidin [34], luteolin [32], and oleuropein [135] on alveolar bone loss and inflammation in a rat model of ligature-induced PD indicating that flavonoids might be an interesting candidate for modulating inflammatory disease.

7.4. Colchicine. Colchicine, a natural compound extracted from Colchicum autumnale, possesses innumerable pharmacological properties, such as anti-inflammatory, antioxidant, antimitotic, and antiresorptive, that has been used to treat a variety of inflammatory diseases [149, 150]. The anti-inflammatory and antioxidant effects of colchicine rely on the inhibition of adhesion, mobilization, and chemotaxis of neutrophils and by the disruption of inflammasome activity (NALP3) and IL-1β secretion. A previous study has shown that colchicine inhibits bone resorption by preventing the release of lysosomal enzymes and blocking osteoclast activity. In this context, Aral et al. investigated the effects of colchicine on cytokine production, apoptosis, alveolar bone loss, and oxidative stress in rats with ligature-induced experimental periodontitis [151]. The animals received two different dosages of colchicine (30 and 100 μg/kg/day) immediately after ligature placement and were sacrificed 11 days after initial treatment. The results showed that colchicine treatment (both dosages) significantly decreased the expression of IL-1β, IL-8, and RANKL; RANKL/OPG ratio; total oxidative stress level; and bone volume ratio and increased total antioxidant suggesting that colchicine has prophylactic potential to prevent the progression of bone loss through anti-inflammatory and antiresorptive properties.

8. Specialized Proresolving Mediators (SPM)

Current key discoveries in the mechanisms of inflammation during PD initiation and progression encouraged the search for new treatment alternatives for PD using proresolving mediators. Resolution of inflammation comprises active biochemical programs that allow inflamed tissue to return to
homeostasis [152, 153]. SPMs are a novel family of oxylipids mediators, including resolvins, maresins, lipoxins, and protectins, derived from omega-3 polyunsaturated fatty acid (PUFA), which regulate the inflammatory process without immunosuppression [7]. The SPMs function in inflammation termination by activating specific mechanisms to restore tissue homeostasis [152, 153]. Briefly, they selectively inhibit leukocyte recruitment, activate macrophage phagocytosis of microorganisms, stimulate infiltration of monocytes, and stimulate the expression of molecules involved in antimicrobial defense [154]. Such SPMs promote tissue repair, eliminate bacteria, increase the host defense, and impact the responses of adaptive immune cells (Figure 3) [39]. The E-series resolvins (RvE1) are biosynthesized from the eicosapentaenoic acid (EPA), and it is considered a stereoselective agonist that interacts with two identified G protein-coupled receptors: BLT1 (expressed on neutrophils) and chemerin receptor 23 (chemR23) expressed on macrophages, monocytes, dendritic cells, and osteoblasts [155, 156]. RvE1 interacts with BLT1 or chemR23 to inhibit leukocyte infiltration and cytokine production, thus promoting the resolution of inflammation [154].

SPMs show significant effectiveness in treating inflammatory conditions including inflammatory pain [157], experimental PD [40, 158, 159], and bone preservation [42]. Furthermore, it has been reported that SPM attenuates atherosclerotic plaque formation in diet- and inflammation-induced atherogenesis [160]. Gao et al. [42] showed that transgenic mice overexpressing the human chemR23 were able to diminish the destruction of the alveolar bone induced by ligature placement. Moreover, local RvE1 treatment accelerated the resolution of bone defects in a craniotomy model. Taken together, RvE1 modulates osteoclast differentiation and bone remodeling, rescuing OPG production and restoring a favorable RANKL/OPG ratio [42]. This data agrees with the previous report that evaluated the impact of RvE1 on bone remodeling in mice, using a calvaria osteolytic model with or without systemic administration of RvE1 [161]. The data demonstrated that RvE1 reduced bone resorption and osteoclastogenesis. RvE1 also negatively regulates osteoclast differentiation, which resulted in a reduction in inflammatory bone resorption, suggesting that RvE1 may be a therapeutic potential for treating inflammatory diseases [161]. Lee et al. [159] also demonstrated that topical application of RvE1 downregulated bone loss induced by ligature placement and decreased the inflammatory process and the number and size of osteoclasts in rats. In addition, RvE1 induced changes in the composition of the local microbiota suggesting the modulation of local inflammation has an important role in forming the subgingival microbiota composition [159].

Hasturk et al. demonstrated that topical application RvE1 was able to prevent initiation and progression of experimental PD and even induce the regeneration of periodontal tissues (alveolar bone, periodontal ligament, and cement) in a rabbit model of ligature-induced bone loss [40, 158]. RvE1 downregulated the progression of PD by decreasing proinflammatory mediators and reducing inflammatory bone loss. Furthermore, RvE1 is able to enhance the clearance of PD-associated bacteria [40, 158]. These outcomes suggest that PD-associated bacteria actively direct the protective bactericidal immune response into a dysfunctional state, which may be reversed by SPMs. The established protective action of SPM aiming in promoting the resolution of inflammation in innumerable animal models of PD makes them an interesting alternative to treat PD [7, 162]. Table 8 describes the primary findings of the selected studies.

9. Probiotics

The manipulation of the intestinal microbiota through probiotics has been proposed to alter bone remodeling during the course of PD both in preclinical studies and in randomized clinical trials. The rationale for this approach is based on the concept that bone health is affected by changes in the intestinal microbiota and therefore, strategies to induce beneficial effects through nutritional supplementation with probiotics have been evidenced. The term probiotics were introduced by Lilly and Stillwell in 1965 [163]. Probiotics are live microorganisms that, when administered in adequate amounts, confer beneficial effects on the host’s health. They repopulate beneficial bacteria, which can help kill pathogenic bacteria and fight infection. Orally administered probiotics can benefit oral health by preventing microbiota growth or modulating mucosal immunity in the oral cavity [164]. Probiotics can help prevent and treat PD through several mechanisms, including direct interaction, competitive exclusion, and modulation of the host’s immune response. Studies show that the treatment strategies conferred by probiotics against PD occur mainly by inhibiting specific pathogens or altering the host’s immune response [165] (Table 9).

Several studies have been published using probiotics for the treatment of experimental PD. Moraes et al. investigated the effects of L. reuteri administration during the development of induced PD in rats [166]. The results showed that treatment with probiotics increased the percentage of bone volume and the thickness and number of trabeculae and decreased bone porosity and trabecular separation. Cardoso et al. evaluated the effects of systemic administration of the probiotic Bifidobacterium animalis HN019 on ligature-induced periodontitis in rats with experimental RA [167]. Probiotic treatment in animals with experimental arthritis and PD reduced alveolar bone loss, TNF-α, and IL-6 levels and increased IL-17 levels compared to those without probiotics. Furthermore, there was a decrease in the levels of anticitrullinated protein antibodies in animals with experimental RA. Ricoldi et al. [168] and Oliveira et al. [169] found similar results using HN019 to treat experimental PD, showing reductions in alveolar bone resorption and connective tissue attachment loss. These results were also observed using different strains of probiotics, including Lactobacillus rhamnosus [170], Lactobacillus brevis CD2 [171], and Lactobacillus gasseri SBT2055 [172].

Some limitations associated with the use of probiotic therapy (difficulty of exogenously administered bacteria in remaining in the oral environment) have stimulated the search for other strategies capable of manipulating the
ecology of the oral biofilm [174]. An interesting approach concerns the nutritional stimulation of beneficial native bacteria to promote oral health. Prebiotics favor changes in microbial composition or activity, aiming to stimulate the growth of health-promoting bacteria in the resident intestinal microbiota, which provides local and systemic benefits for the host’s health. By definition, prebiotics are selectively fermented ingredients that allow specific changes, either in the composition and/or activity of the gastrointestinal tract microflora, that confer benefits to the host, well-being, and health. They are substances not digested by enzymes, salts, and acids produced by the body. Currently, oligosaccharides (fructooligosaccharides and galactooligosaccharides) can be selected prebiotics. Their mechanism of action occurs through the following: (a) improvement in the growth of resident commensal intestinal bacteria, particularly *bifidobacteria* and *lactobacilli*; (b) they exert a direct effect on the host by stimulating the expression of IL-10 and INF-γ, increased secretion of immunoglobulin (IgA), and modulation of inflammatory responses in pathogens [174].

Prebiotics and probiotics often work synergistically and, when combined in the same product, are known as symbiotics. Symbiotics contain both probiotic and prebiotic components. The rationale for such products is that the combination increases the survival of probiotic bacteria in the passage through the proximal region of the gastrointestinal tract, improving colonization of the probiotic in the large intestine, stimulating the effect on the growth of endogenous flora. The main prebiotics evaluated in humans are fructans and galactans. Mannan oligosaccharides (MOS) are also gaining importance. Levi et al. [173] performed a preclinical study in rats demonstrating that animals with ligature-induced PD showed changes in intestinal morphology compared to animals without the disease, confirming the possible relationship between oral and intestinal dysbiosis. When animals with experimental PD were treated with MOS, the intestinal morphology became more similar to that of animals without disease, demonstrating prebiotics’ protective role in the intestinal environment under conditions of oral dysbiosis. Furthermore, animals with PD and MOS had less severe PD than those not treated with MOS. In fact, recent scientific evidence suggests that manipulating the microbiota through prebiotics and probiotics confers health benefits on the host through different mechanisms, improving periodontal health and other common skeletal diseases such as arthritis and osteoporosis.

10. Vitamins

10.1. Vitamin C. Vitamin C has powerful antioxidant properties and has been the focus of several investigations to manage inflammatory diseases, including PD [175]. Deficiency in the levels of systemic vitamin C might affect the gingival and connective tissue increasing the expression of
inflammatory cells and impairing collagen formation, thus worsening the severity of periodontitis [176, 177]. A study conducted by Akman et al. evaluated the therapeutic effect of vitamin C on alveolar bone loss in rats with ligature-induced experimental periodontitis [178]. The ligatures were maintained for 5 weeks to induce periodontal breakdown, and then, they were removed. Treatments with vitamin C or vitamin C plus alpha lipoic acid (ALA—50 mg/kg) were initiated immediately after ligature removal with a single intragastric dose for 15 days. Levels of bone alkaline phosphatase and myeloperoxidase activity were measured in the gingival tissues, and expressions of RANKL and bone density were determined histologically. The results indicated that vitamin C and ALA inhibit inflammatory bone resorption and osteoclast activation suggesting its beneficial improvements in osteoclast-mediated bone resorption [178].

10.2. Vitamin B. Previously published studies on the effects of food and nutrients with antioxidant and anti-inflammatory activities have constantly been linked to improvements in the periodontal status in animal models [179] and also in patients [180] when treated with vitamin B. Vitamin B complex, a class of water-soluble vitamins, play pivotal functions in cell metabolism [179]. The vitamin B complex includes eight different vitamins which differ in their chemical composition and pharmacological properties [181]. Studies have shown that vitamin B complex is important in soft wound healing and gingival health, and some studies have indicated that vitamin B12 [182], vitamin B9 [183], vitamins B1, B2, B3, B5, B6, and B7 reduced the periodontal destruction and tooth mobility [184]. Recently, Akpınar et al. investigated the effects of vitamin B complex supplementation on the progression of experimental periodontitis in rats. Daily systemic administration of vitamin B by oral gavage was initiated immediately after ligature placement and followed by 11 days. Then, animals were sacrificed and bone tissue samples were collected for histomorphometric evaluation. The authors showed that vitamin B administration increased osteoblast activity, diminished osteoclast numbers, and reduced alveolar bone loss in rat with experimental PD, suggesting beneficial effects of vitamin B complex on the bone tissue.

10.3. Vitamins D and K. Vitamin D receptor has been found on many immune cells, such as macrophages, dendritic cells, and T and B cells [185]. Additionally, it has been shown that vitamin D inhibits proinflammatory processes by suppressing the overactivity of CD4+ Th1, Th2, and Th17 cells and the production of their related cytokines such as IL-2, IFN-gamma, and TNF-alpha [186, 187]. Vitamin D has also regulatory effects on bone formation markers, such as osteocalcin and osteopontin, and acts as an immune modulator in inflammatory conditions [185]. Vitamin K plays important roles on bone protection, in the proliferation of bone marrow mesenchymal stem cells, in stimulating osteoblast differentiation and inhibiting adipocyte differentiation. In addition, it can protect osteoblasts and reduce apoptosis. Due to its anabolic effects on bone, the effect of vitamins B and K on gingival inflammation and alveolar bone destruction in rats was investigated by Aral et al. [188]. In this study, periodontitis was induced by placing cotton ligatures around the maxillary first molar for 7 days. Then, ligatures were removed, and tooth received scaling and root planning followed by oral gavage with vitamins D and K or a combination of vitamins D and K for 10 days. The results indicated that alveolar bone loss in rats administrated with vitamin D or K did not differ from rats without treatment, suggesting that this approach has no positive effects on alveolar bone and in gingival inflammatory markers.

11. Conclusion

This comprehensive review of the literature summarizes the main findings of studies that have used pharmacological drugs to manage experimental PD. The use of modulators of the immune host response or antiresorptive medications offers interesting alternatives to inhibit bone loss and decrease the inflammatory infiltrate in the connective tissue. All those treatments tested can help modulate the host inflammatory response and ameliorate the progression of the experimental disease. As stated earlier, the primary treatment of PD is through a mechanical approach, SRP, to remove the attached biofilm into the tooth and root surface. However, this local treatment does not respond equally well in susceptible patients. Thus, adjunctive therapies that decrease the inflammatory host response play an important role in achieving better clinical outcomes, especially in patients with associated comorbidities, such as diabetes mellitus and rheumatoid arthritis. It is important to bear in mind that some of the included drugs in this review, i.e., bisphosphonate, biological agents, and RANKL and CtsK inhibitors, possess some side effects that might limit their clinical use. Therefore, herbal medicine and supplementation with omega 3 and probiotics have gained growing attention due to its modulatory and antiresorptive activities and the lack of side effects being considered promising alternatives as adjunctive to SRP in susceptible patients.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflicts of interest to report regarding the present study.

Authors’ Contributions

The authors confirm contribution to the paper as follows: study conception and design: JAC and RSM; draft manuscript preparation: ALRP, BSM, EBBP, FASM, JAC, and RSM. All authors reviewed the article text and approved the final version of the manuscript.
Acknowledgments

de Molon RS was supported by a grant provided by CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) grant # 88887.583248/2020-00.

References

[1] D. F. Kinane, P. G. Stathopoulou, and P. N. Papapanou, “Periodontal diseases,” Nat Rev Dis Primers, vol. 3, p. 17038, 2017.

[2] Z. S. Natto, R. H. Abu Ahmad, L. T. Alsharif et al., “Chronic periodontitis case definitions and confounders in periodontal research: a systematic assessment,” Biomed Res Int, vol. 2018, p. 4578782, 2018.

[3] M. S. Tonetti, H. Greenwell, and K. S. Kornman, “Staging and grading of periodontitis: Framework and proposal of a new classification and case definition,” J Periodontol, vol. 89, Suppl 1, pp. S159–S172, 2018.

[4] B. L. Pihlstrom, B. S. Michalowicz, and N. W. Johnson, “Periodontal diseases,” Lancet, vol. 366, no. 9499, pp. 1809–1820, 2005.

[5] G. Najishengallil, T. Chavakis, and J. D. Lambris, “Current understanding of periodontal disease pathogenesis and targets for host-modulation therapy,” Periodontol, vol. 84, no. 1, pp. 14–34, 2000.

[6] R. S. de Molon, E. D. de Avila, J. A. Cirelli, and J. P. Steffens, “Periodontal research contributions to basic sciences: from cell communication and host-parasite interactions to inflammation and bone biology,” Biocell, vol. 46, no. 3, pp. 633–638, 2022.

[7] M. G. Balta, E. Papathanasiou, I. J. Blix, and T. E. Van Dyke, “Host modulation and treatment of periodontal disease,” J Dent Res, vol. 100, no. 8, pp. 798–809, 2021.

[8] K. R. Phipps and V. J. Stevens, “Relative contribution of caries and periodontal disease in adult tooth loss for an HMO dental population,” J Public Health Dent, vol. 55, no. 4, pp. 250–252, 1995.

[9] G. N. Belibasakis, D. Reddi, and N. Bostancı, “Porphyromonas gingivalis induces RANKL in T-cells,” Inflammation, vol. 34, no. 2, pp. 133–138, 2011.

[10] T. Yucel-Lindberg and T. Bage, “Inflammatory mediators in the pathogenesis of periodontitis,” Expert Rev Mol Med, vol. 15, article e7, 2013.

[11] R. S. de Molon, C. Rossa Jr., R. M. Thurlings, J. A. Cirelli, and M. I. Koenders, “Linkage of periodontitis and rheumatoid arthritis: current evidence and potential biological interactions,” International Journal of molecular sciences, vol. 20, no. 18, 2019.

[12] D. L. Lacey, W. J. Boyle, W. S. Simonet et al., “Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab,” Nat Rev Drug Discov, vol. 11, no. 5, pp. 401–419, 2012.

[13] J. Bhuvaneswarri, B. Gita, and S. C. Chandrasekaran, “Detection of rankl positive cells in gingival tissue in healthy & chronic periodontal disease patients-a comparative study,” J Clin Diagn Res, vol. 8, pp. 31–34, 2014.

[14] H. W. G. I. Birkedal-Hansen, W. G. I. Moore, M. K. Bodden et al., “Matrix metalloproteinases: a review,” Crit Rev Oral Biol Med, vol. 4, no. 2, pp. 197–250, 1993.

[15] M. A. Taubman, P. Valverde, X. Han, and T. Kawai, “Immune response: the key to bone resorption in periodontal disease,” J Periodontol, vol. 76, 11 Suppl, pp. 2033–2041, 2005.

[16] J. W. Krayev, R. S. Leite, and K. L. Kirkwood, "Non-surgical chemotherapeutic treatment strategies for the management of periodontal diseases," Dent Clin North Am, vol. 54, no. 1, pp. 13–33, 2010.

[17] X. Wang, Z. Jia, Y. Almoshari, S. M. Lele, R. A. Reinhardt, and D. Wang, "Local application of pyrophosphorylated simvastatin prevents experimental periodontitis," Pharm Res, vol. 35, no. 8, p. 164, 2018.

[18] P. M. Preshaw, "Host modulation therapy with anti-inflammatory agents," Periodontol, vol. 76, no. 1, pp. 131–149, 2000.

[19] L. M. Golub, H. M. Lee, M. E. Ryan, W. V. Giannobile, J. Payne, and T. Sorsa, "Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms," Adv Dent Res, vol. 12, no. 2, pp. 12–26, 1998.

[20] L. M. Golub, M. Wolf, S. Roberts, H. M. Lee, M. Leung, and G. S. Payonk, "Treating periodontal diseases by blocking tissue-destructive enzymes," Journal of the American Dental Association, vol. 125, no. 2, pp. 163–169, 1994.

[21] L. M. Golub, M. S. Elburki, C. Walker et al., "Non-antibacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases," Int Dent J, vol. 66, no. 3, pp. 127–135, 2016.

[22] A. Yagan, S. Kesim, and N. Liman, "Effect of low-dose doxycycline on serum oxidative status, gingival antioxidant levels, and alveolar bone loss in experimental periodontitis in rats," J Periodontol, vol. 85, no. 3, pp. 478–489, 2014.

[23] G. Greenstein, "Local drug delivery in the treatment of periodontal diseases: assessing the clinical significance of the results," J Periodontol, vol. 77, no. 4, pp. 565–578, 2006.

[24] L. Hao, J. Chen, Z. Zhu et al., "Odanacatib, a cathepsin K-specific inhibitor, inhibits inflammation and bone loss caused by periodontal diseases," J Periodontol, vol. 86, no. 8, pp. 972–983, 2015.

[25] W. Chen, B. Gao, L. Hao et al., "The silencing of cathepsin K used in gene therapy for periodontal disease reveals the role of cathepsin K in chronic infection and inflammation," J Periodontal Res, vol. 51, no. 5, pp. 647–660, 2016.

[26] Q. Jin, J. A. Cirelli, C. H. Park et al., "RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis," J Periodontol, vol. 78, no. 7, pp. 1300–1308, 2007.

[27] N. C. Karakan, A. Akpinar, F. Goze, and O. Poyraz, "Investigating the effects of systemically administered strontium ranelate on alveolar bone loss histomorphometrically and histopathologically on experimental periodontitis in rats," J Periodontol, vol. 88, no. 2, pp. e24–e31, 2017.

[28] Y. Ozaki, T. Morozumi, K. Watanabe et al., "Inhibitory effect of omega-3 fatty acids on alveolar bone resorption and osteoclast differentiation," J Oral Sci, vol. 62, no. 3, pp. 298–302, 2020.

[29] F. Stralberg, A. Kassem, F. Kasprzykowski et al., "Inhibition of lipopolysaccharide-induced osteoclast formation and bone resorption in vitro and in vivo by cysteine proteinase inhibitors," J Leukoc Biol, vol. 101, no. 5, pp. 1233–1243, 2017.

[30] H. H. Wang, H.-M. Lee, V. Raja et al., "Enhanced efficacy of chemically modified curcumin in experimental periodontitis:
systemic implications,” J Exp Pharmcol, vol. 11, pp. 1–14, 2019.

[31] L. M. G. Zambrano, D. A. Brandao, F. R. G. Rocha et al., “Local administration of curcumin-loaded nanoparticles effectively inhibits inflammation and bone resorption associated with experimental periodontal disease,” Sci Rep, vol. 8, no. 1, p. 6652, 2018.

[32] H. Balci Yuce, H. Toker, A. Yildirim, M. B. Tekin, F. Gevrek, and N. Altunbas, “The effect of luteolin in prevention of periodontal disease in Wistar rats,” J Periodontol, vol. 90, no. 12, pp. 1481–1489, 2019.

[33] Y. H. Wu, R. Kuraji, Y. Taya, H. Ito, and Y. Numabe, “Effects of theaflavins on tissue inflammation and bone resorption on experimental periodontitis in rats,” J Periodontal Res, vol. 53, no. 6, pp. 1009–1019, 2018.

[34] P.-. J. Kuo, E. Fu, C.-. Y. Lin et al., “Ameliorative effect of hesperidin on ligation-induced periodontitis in rats,” J Periodontol, vol. 90, no. 3, pp. 271–280, 2019.

[35] J. De Almeida, E. Ervolino, L. H. Bonfi, L. Gao, D. Faibish, G. Fredman et al., M. M. Moreira, V. Bradaschia-Correa, N. D. Marques, L. B. L. M. G. Zambrano, D. A. Brandao, F. R. G. Rocha et al., B. S. Herrera, T. Ohira, L. Gao et al., L. M. Marins, M. H. Napimoga, F. de Souza Malta et al., R. A. Ribeiro, and G. A. Brito, “Radiographic and histological study of the inflammatory bone resorption in vivo and suppresses osteoclastogenesis in vitro,” J Periodontal Res, vol. 53, no. 3, pp. 569–578, 2021.

[36] W. Wei, J. Ren, W. Yin et al., “Inhibition of Ctsk modulates periodontitis with arthritis via downregulation of TLR9 and autophagy,” Cell Prolif, vol. 53, no. 1, article e17272, 2020.

[37] R. S. de Molon, C. H. Park, Q. Jin, J. Sugai, and J. A. Cirelli, “Characterization of ligature-induced experimental periodontitis,” Micros Res Tech, vol. 81, no. 12, pp. 1412–1421, 2018.

[38] R. S. de Molon, E. D. de Avila, A. V. B. Nogueira et al., “Evaluation of the host response in various models of induced periodontal disease in mice,” J Periodontol, vol. 85, no. 3, pp. 465–477, 2014.

[39] A. V. B. Nogueira, R. S. de Molon, M. Nokhbehaim, J. Deschner, and J. A. Cirelli, “Contribution of biomechanical forces to inflammation-induced bone resorption,” J Clin Periodontol, vol. 44, no. 1, pp. 31–41, 2017.

[40] R. S. de Molon, V. I. Mascarenhas, E. D. de Avila et al., “Long-term evaluation of oral gavage with periodontopathogens or ligature induction of experimental periodontal disease in mice,” Clin Oral Invest, vol. 20, no. 6, pp. 1203–1216, 2016.

[41] J. Cavagni, L. C. de Macedo, E. J. Gaio et al., “Obesity and hyperlipidemia modulate alveolar bone loss in Wistar rats,” J Periodontol, vol. 87, no. 2, pp. e9–17, 2016.

[42] M. E. S. Lopes, C. C. Marcantoniio, R. S. de Molon et al., “Obesity influences the proteome of periodontal ligament tissues following periodontitis induction in rats,” J Periodontal Res, 2022.

[43] B. Rath-Deschner, S. Memmert, A. Damanaki et al., “CXCL5, CXCL8, and CXCL10 regulation by bacteria and mechanical forces in periodontium,” Ann Anat, vol. 234, article 151648, 2021.

[44] A. V. Nogueira, M. Nokhbehaim, S. Tekin et al., “Resistin is increased in periodontal cells and tissues: in vitro and in vivo studies,” Mediators Inflamm, vol. 2020, p. 9817095, 2020.

[45] M. M. Belluci, R. S. de Molon, S. T. Carlos Rossa Jr. et al., “Severe magnesium deficiency compromises systemic bone mineral density and aggravates inflammatory bone resorption,” J Nutr Biochem, vol. 77, article 108301, 2020.

[46] R. S. de Molon, E. D. de Avila, and J. A. Cirelli, “Host responses induced by different animal models of periodontal disease: a literature review,” J Invest Clin Dent, vol. 4, no. 4, pp. 211–218, 2013.

[47] D. T. Graves, J. Kang, O. Andriankaja, K. Wada, and C. Rossa Jr., “Animal models to study host-bacteria interactions involved in periodontitis,” Front Oral Biol, vol. 15, pp. 117–132, 2012.

[48] D. T. Graves, D. Fine, Y. T. Teng, T. E. Van Dyke, and G. Hajishengallis, “The use of rodent models to investigate host-bacteria interactions related to periodontal diseases,” J Clin Periodontol, vol. 35, no. 2, pp. 89–105, 2008.
[61] M. R. McClung, M. L. O'Donoghue, S. E. Papapoulos et al., "Pam2CSK4 (TLR2 agonist) induces periodontal destruction in mice," *Braz Oral Res*, vol. 34, article e012, 2020.

[62] R. A. Dodds, I. E. James, D. Rieman et al., "Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption," *J Bone Miner Res*, vol. 16, no. 3, pp. 478–486, 2001.

[63] K.-I. Tezuka, Y. Tezuka, A. Maejima et al., "Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts," *J Biol Chem*, vol. 269, no. 2, pp. 1106–1109, 1994.

[64] P. Garnero, O. Borel, I. Byrjalsen et al., "The collagenolytic activity of cathepsin K is unique among mammalian proteinases," *J Biol Chem*, vol. 273, no. 48, pp. 32347–32352, 1998.

[65] J. Christensen and V. P. Shastri, "Matrix-metalloproteinase-9 is cleaved and activated by cathepsin K," *BMC Res Notes*, vol. 8, p. 322, 2015.

[66] W. Kafrenah, D. Bromme, D. J. Buttle, L. J. Croucher, and A. P. Hollander, "Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix," *Biochem J*, vol. 331, no. 3, pp. 727–732, 1998.

[67] M. T. Drake, B. L. Clarke, M. J. Oursler, and S. Khosla, "Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned," *Endocr Rev*, vol. 38, no. 4, pp. 325–350, 2017.

[68] R. J. Votta, M. A. Levy, A. Badger et al., "Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo," *J Bone Miner Res*, vol. 12, no. 9, pp. 1396–1406, 1997.

[69] S. K. Thompson, S. M. Halbert, M. J. Bossard et al., "Design of potent and selective human cathepsin K inhibitors that span the active site," *Proc Natl Acad Sci U S A*, vol. 94, no. 26, pp. 14249–14254, 1997.

[70] D. S. Yamashita and R. A. Dodds, "Cathepsin K and the design of inhibitors of cathepsin K," *Curr Pharm Des*, vol. 6, no. 1, pp. 1–24, 2000.

[71] J. Han, L. Wei, W. Xu et al., "CTSK inhibitor exerts its anti-obesity effects through regulating adipocyte differentiation in high-fat diet induced obese mice," *Endocr J*, vol. 62, no. 4, pp. 309–317, 2015.

[72] Y. Yue, W. Yin, Q. Yang et al., "Inhibition of cathepsin K alleviates autophagy-related inflammation in periodontitis-aggravating arthritis," *Infect Immun*, vol. 88, no. 12, 2020.

[73] A. G. Costa, N. E. Cusano, B. C. Silva, S. Cremer, and J. P. Bilezikian, "Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis," *Nat Rev Rheumatol*, vol. 7, no. 8, pp. 447–456, 2011.

[74] M. R. McClung, M. L. O'Donoghue, S. E. Papapoulos et al., "Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study," *Lancet Diabetes Endocrinol*, vol. 7, no. 4, pp. 389–911, 2019.

[75] W. Pan, W. Yin, L. Yang et al., "Inhibition of Ctsk alleviates periodontitis and comorbid rheumatoid arthritis via down-regulation of the TLR9 signalling pathway," *J Clin Periodontol*, vol. 46, no. 3, pp. 286–296, 2019.

[76] N. Da Ponte Leguizamón, R. S. de Molon, G. Coelho-Nunes et al., "Phytocystatin CsnCPI-2 reduces osteoclastogenesis and alveolar bone loss," *J Dent Res*, vol. 101, no. 2, pp. 216–225, 2022.

[77] M. Asagiri, T. Hirai, T. Kunigami et al., "Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis," *Science*, vol. 319, no. 5863, pp. 624–627, 2008.

[78] R. Dai, Z. Wu, H. Y. Chu et al., "Cathepsin K: the action in and beyond bone," *Front Cell Dev Biol*, vol. 8, p. 433, 2020.

[79] D. Keppler, "Towards novel anti-cancer strategies based on cystatin function," *Cancer Lett*, vol. 235, no. 2, pp. 159–176, 2006.

[80] M. Brage, A. Lie, M. Ransjö et al., "Osteoclastogenesis is decreased by cysteine proteinase inhibitors," *Bone*, vol. 34, no. 3, pp. 412–424, 2004.

[81] U. H. Lerner and A. Grubb, "Human cystatin C, a cysteine proteinase inhibitor, inhibits bone resorption in vitro stimulated by parathyroid hormone and parathyroid hormone-related peptide of malignancy," *J Bone Miner Res*, vol. 7, no. 4, pp. 433–440, 1992.

[82] N. D. P. Leguizamon, E. M. Rodrigues, M. L. de Campos et al., "In vivo and in vitro anti-inflammatory and pro-osteogenic effects of citrus cystatin CsnCPI-2," *Cytokine*, vol. 123, article 154760, 2019.

[83] S. P. Luckman, D. E. Hughes, F. P. Coxon, R. Graham, G. Russell, and M. J. Rogers, "Nitrogen-containing bisphosphonates inhibit the mevalone pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras," *J Bone Miner Res*, vol. 13, no. 4, pp. 581–589, 1998.

[84] D. B. Kimmel, "Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates," *J Dent Res*, vol. 86, no. 11, pp. 1022–1033, 2007.

[85] R. Baron, S. Ferrari, and R. G. Russell, "Denosumab and bisphosphonates: different mechanisms of action and effects," *Bone*, vol. 48, no. 4, pp. 677–692, 2011.

[86] S. L. Ruggiero, T. B. Dodson, L. A. Assael, R. Landesberg, R. E. Marx, and B. Mehrotra, "American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws 2009 update," *J Oral Maxillofac Surg*, vol. 67, 5 Suppl, pp. 2–12, 2009.

[87] S. L. Ruggiero, T. B. Dodson, T. Aghaloo, E. R. Carlson, B. B. Ward, and D. Kademan, "American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw 2014 update," *J Oral Maxillofac Surg*, vol. 72, no. 10, pp. 1938–1956, 2014.

[88] S. L. Ruggiero and B. Mehrotra, "Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management," *Annu Rev Med*, vol. 60, pp. 85–96, 2009.

[89] S. Oktay, S. S. Chukkapalli, M. F. Rivera-Kweh, I. M. Velsko, L. S. Holliday, and L. Kesavalu, "Periodontitis in rats induces systemic oxidative stress that is controlled by bone-targeted antiresorptives," *J Periodontol*, vol. 86, no. 1, pp. 137–145, 2015.

[90] C. S. Santinoni, F. M. Silveira, M. L. Caldeira et al., "Topical sodium alendronate combined or not with photodynamic therapy as an adjunct to scaling and root planing: histochemical and immunohistochemical study in rats," *J Periodontal Res*, vol. 55, no. 6, pp. 850–858, 2020.

[91] B. Carvalho Dutra, A. Oliveira, P. A. D. Oliveira, L. O. Miranda Cota, J. O. Silveira, and F. O. Costa, "Effects of topical application of 1% sodium alendronate gel in the surgical treatment of periodontal intrabony defects: a 6-month..."
randomized controlled clinical trial,” *J Periodontol*, vol. 90, no. 10, pp. 1079–1087, 2019.

[92] V. Sheokand, V. S. Chadha, and P. Palwankar, “The comparative evaluation of 1% alendronate gel as local drug delivery system in chronic periodontitis in smokers and non-smokers: randomized clinical trial,” *J Oral Biol Craniofac Res*, vol. 9, no. 2, pp. 198–203, 2019.

[93] D. Kanoriya, A. R. Pradeep, V. Garg, and S. Singhal, “Mandibular degree II furcation defects treatment with platelet-rich fibrin and 1% alendronate gel combination: a randomized controlled clinical trial,” *J Periodontol*, vol. 88, no. 3, pp. 250–258, 2017.

[94] M. A. Brunsvold, E. S. Chaves, K. S. Kornman, T. B. Aufdemorte, and R. Wood, “Effects of a bisphosphonate on experimental periodontitis in monkeys,” *J Periodontol*, vol. 63, no. 10, pp. 825–830, 1992.

[95] F. Muniz, B. F. D. Silva, C. R. Goulart, C. R. Goulart, T. M. D. Silveira, and T. M. Martins, “Effect of adjuvant bisphosphonates on treatment of periodontitis: systematic review with meta-analyses,” *J Oral Biol Craniofac Res*, vol. 11, no. 2, pp. 158–168, 2021.

[96] Y.-T. A. Teng, H. Nguyen, X. Gao et al., “Functional human T-cell immunity and osteoproetin IgG control alveolar bone destruction in periodontal infection,” *J Clin Invest*, vol. 106, no. 6, pp. R59–R67, 2000.

[97] D. A. Mahamed, A. Marleau, M. Alnæeli et al., “G(+) anaerobes-reactive CD4+ T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice,” *Diabetes*, vol. 54, no. 5, pp. 1477–1486, 2005.

[98] M. Kuritani, N. Sakai, A. Karakawa et al., “Anti-mouse RANKL antibodies inhibit alveolar bone destruction in periodontitis model mice,” *Biol Pharm Bull*, vol. 41, no. 4, pp. 637–643, 2018.

[99] A. Soundia, D. Hadaya, N. Esfandi et al., “Osteonecrosis of the jaws (ONJ) in mice after extraction of teeth with periapical disease,” *Bone*, vol. 90, pp. 133–141, 2016.

[100] R. S. de Molon, H. Shimamoto, O. Bezuglaia et al., “OPG-Fc but not zoledronic acid discontinuation reverses osteonecrosis of the jaws (ONJ) in mice,” *J Bone Miner Res*, vol. 30, no. 9, pp. 1627–1640, 2015.

[101] R. S. de Molon, S. Cheong, O. Bezuglaia et al., “Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model,” *Bone*, vol. 68, pp. 11–19, 2014.

[102] R. S. de Molon, C. Hsu, O. Bezuglaia et al., “Rheumatoid arthritis exacerbates the severity of osteonecrosis of the jaws (ONJ) in mice. a randomized, prospective, controlled animal study,” *J Bone Miner Res*, vol. 31, no. 8, pp. 1596–1607, 2016.

[103] A. Panahifar, W. P. Maksymowych, and M. R. Doschak, “Potential mechanism of alendronate inhibition of osteocyte formation in the rat model of post-traumatic osteoarthritis: evaluation of elemental strontium as a molecular tracer of bone formation,” *Osteoarthritis Cartilage*, vol. 20, no. 7, pp. 694–702, 2012.

[104] J. Rodriguez, N. D. Escudero, and P. M. Mandalunis, “Effect of strontium ranelate on bone remodeling,” *Acta Odontol Latinoam*, vol. 25, no. 2, pp. 208–213, 2012.

[105] P. J. Marie, “Strontium ranelate: a physiological approach for optimizing bone formation and resorption,” *Bone*, vol. 38, 2 Suppl 1, pp. S10–S14, 2006.

[106] P. Ammann, I. Badoud, S. Barraud, R. Dayer, and R. Rizzoli, “Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength,” *J Bone Miner Res*, vol. 22, no. 9, pp. 1419–1425, 2007.

[107] N. Chattopadhyay, S. J. Quinn, O. Kifor, C. Ye, and E. M. Brown, “The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation,” *Biochem Pharmacol*, vol. 74, no. 3, pp. 438–447, 2007.

[108] P. J. Marie, M. Hott, D. Modrowski et al., “An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats,” *J Bone Miner Res*, vol. 8, no. 5, pp. 607–615, 1993.

[109] A. Bruel, J. B. Vegger, A. C. Raffalt, J. E. Andersen, and J. S. Thomsen, “PTH (1-34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats,” *Bone*, vol. 53, no. 1, pp. 51–58, 2013.

[110] Y. L. Ma, Q. Q. Zeng, L. L. Porras et al., “Teriparatide [rhPTH (1-34)], but not strontium ranelate, demonstrated bone anabolic efficacy in mature, osteopenic, ovariecctomized rats,” *Endocrinology*, vol. 152, no. 5, pp. 1767–1778, 2011.

[111] R. B. Souza, F. I. F. Gomes, K. M. A. Pereira et al., “Strontium ranelate elevates expression of heme oxygenase-1 and decreases alveolar bone loss in rats,” *J Maxillofacio Res*, vol. 9, no. 4, article e4, 2018.

[112] R. Di Paola, E. Mazzon, C. Muia et al., “Effects of etanercept, a tumour necrosis factor-alpha antagonist, in an experimental model of periodontitis in rats,” *Br J Pharmacol*, vol. 150, no. 3, pp. 286–297, 2007.

[113] T. W. Oates, D. T. Graves, and D. L. Cochran, “Clinical, radiographic and biochemical assessment of IL-1/TNF-alpha antagonist inhibition of bone loss in experimental periodontitis,” *J Clin Periodontol*, vol. 29, no. 2, pp. 137–143, 2002.

[114] A. Vieira, H. Gustavo, A. C. A. Rivas et al., “Specific inhibition of IL-6 receptor attenuates inflammatory bone loss in experimental periodontitis,” *J Periodontol*, vol. 92, no. 10, pp. 1460–1469, 2021.

[115] M. B. Grauballe, J. A. Ostergaard, S. Schou, A. Flyvbjerg, and P. Holmstrup, “Effects of TNF-alpha blocking on experimental periodontitis and type 2 diabetes in obese diabetic Zucker rats,” *J Clin Periodontol*, vol. 42, no. 9, pp. 807–816, 2015.

[116] M. B. Grauballe, D. Belström, J. A. Ostergaard et al., “Ligature-associated bacterial profiles are linked to type 2 diabetes mellitus in a rat model and influenced by antibody treatment against TNF-alpha or RAGE,” *Clin Exp Dent Res*, vol. 3, no. 1, pp. 25–31, 2017.

[117] C. M. Queiroz-Junior, R. L. Bessoni, V. V. Costa, D. G. Souza, M. M. Teixeira, and T. A. Silva, “Preventive and therapeutic anti-TNF-alpha therapy with pentoxifylline decreases arthritis and the associated periodontal co-morbidity in mice,” *Life Sci*, vol. 93, no. 9-11, pp. 423–428, 2013.

[118] J. A. Cirelli, C. H. Park, K. MacKool et al., “AAV2/1-TNF-Fc gene delivery prevents periodontal disease progression,” *Gene Ther*, vol. 16, no. 3, pp. 426–436, 2009.

[119] S. Bisht, M. Mizuma, G. Feldmann et al., “Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer,” *Mol Cancer Ther*, vol. 9, no. 8, pp. 2255–2264, 2010.

[120] D. de Almeida Brandao, L. C. Spolidorio, F. Johnson, L. M. Golub, M. R. Guimarães-Stabili, and C. Rossa Jr., “Dose-response assessment of chemically modified curcumin in
experimental periodontitis,” *J Periodontol*, vol. 90, no. 5, pp. 535–545, 2019.

[121] M. S. Elburki, C. Rossa, M. R. Guimaraes et al., “A novel chemically modified curcinum reduces severity of experimental periodontal disease in rats: initial observations,” *Mediators Inflammm*, vol. 2014, article 959471, 2014.

[122] A. M. Sha and B. T. Garib, “Antibacterial effect of curcinum against clinically isolated Porphyromonas gingivalis and connective tissue reactions to curcinum gel in the subcutaneous tissue of rats,” *Biomed Res Int*, vol. 2019, p. 6810936, 2019.

[123] C. J. Xiao, X. J. Yu, J. L. Xie, S. Liu, and S. Li, “Protective effect and related mechanisms of curcinum in rat experimental periodontitis,” *Head Face Med*, vol. 14, no. 1, p. 12, 2018.

[124] Y. Gu, H.-M. Lee, N. Napolitano et al., “4-Methoxyxycarbonyl curcinum: a unique inhibitor of both inflammatory mediators and periodontal inflammation,” *Mediators Inflamm*, vol. 2013, article 329740, 2013.

[125] S. P. Pimentel, M. Z. Casati, F. V. Ribeiro et al., “Impact of natural curcinum on the progression of experimental periodontitis in diabetic rats,” *J Periodontal Res*, vol. 55, no. 1, pp. 41–50, 2020.

[126] M. G. Corrêa, P. R. Pires, F. V. Ribeiro et al., “Systemic treatment with resveratrol and/or curcinum reduces the progression of experimental periodontitis in rats,” *J Periodontal Res*, vol. 52, no. 2, pp. 201–209, 2017.

[127] M. S. Elburki, D. D. Moore, N. G. Terezakis et al., “A novel chemically modified curcinum reduces inflammation-mediated connective tissue breakdown in a rat model of diabetes: periodontal and systemic effects,” *J Periodontal Res*, vol. 52, no. 2, pp. 186–200, 2017.

[128] Y. Zhang, Y. Gu, H.-M. Lee et al., “Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcinums,” *Curr Med Chem*, vol. 19, no. 25, pp. 4348–4358, 2012.

[129] B. Kumar, V. Singh, R. Shankar, K. Kumar, and R. K. Rawal, “Synthetic and medicinal perspective of structurally modified curcinums,” *Curr Top Med Chem*, vol. 17, no. 2, pp. 148–161, 2017.

[130] G. S. Viana, M. A. Bandeira, and F. J. Matos, “Analgesic and antiinflammatory effects of chalcones isolated from Myrciadrusei urundeuva allemao,” *Phytotherapy Research*, vol. 10, no. 2-3, pp. 189–195, 2003.

[131] S. M. Souza, L. C. Aquino, A. C. Milach Jr., M. A. Bandeira, M. E. Nobre, and G. S. Viana, “Antinflammatory and antilucer properties of tannins from Myrciadrusei urundeuva Allemao (Anacardiaceae) in rodents,” *Phytother Res*, vol. 21, no. 3, pp. 220–225, 2007.

[132] E.-G. Jung, K.-I. Han, H.-J. Kwon et al., “Anti-inflammatory activity of sappanchalcone isolated from Caesalpinia sappan L. in a collagen-induced arthritis mouse model,” *Arch Pharm Res*, vol. 38, no. 6, pp. 973–983, 2015.

[133] X. Chen, X. Cai, R. Le et al., “Isoquiritigenin protects against sepsis-induced lung and liver injury by reducing inflammatory responses,” *Biochem Biophys Res Commun*, vol. 496, no. 2, pp. 245–252, 2018.

[134] M. A. Botelho, V. S. Rao, D. Montenegro et al., “Effects of a herbal gel containing carvacrol and chalcones on alveolar bone resorption in rats on experimental periodontitis,” *Phytother Res*, vol. 22, no. 4, pp. 442–449, 2008.

[135] M. M. Taskan, H. Balci Yuce, O. Karatas, F. Gevrek, and H. Toker, “Evaluation of the effect of oleuropein on alveolar bone loss, inflammation, and apoptosis in experimental periodontitis,” *J Periodontal Res*, vol. 54, no. 6, pp. 624–632, 2019.

[136] E. Middleton Jr., C. Kandaswami, and T. C. Theoharides, “The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer,” *Pharmacol Rev*, vol. 52, no. 4, pp. 673–751, 2000.

[137] J. de Souza Carvalho, D. Ramadan, V. de Paiva Gonçalves et al., “Impact of citrus flavonoid supplementation on inflammation in lipopolysaccharide-induced periodontal disease in mice,” *Food Funct.*, 2021.

[138] W. C. Cheng, R. Y. Huang, C. Y. Chiang et al., “Ameliorative effect of quercitin on the destruction caused by experimental periodontitis in rats,” *J Periodontal Res*, vol. 45, no. 6, pp. 788–795, 2010.

[139] E.-Y. Choi, S. H. Bae, M. H. Ha et al., “Genistein suppresses Prevotella intermedia lipopolysaccharide-induced inflammatory response in macrophages and attenuates alveolar bone loss in ligation-induced periodontitis,” *Arch Oral Biol*, vol. 62, pp. 70–79, 2016.

[140] E. Gugliandolo, R. Fusco, R. D’Amico et al., “Treatment with a flavonoid-rich fraction of bergamot juice improved lipopolysaccharide-induced periodontitis in rats,” *Front Pharmacol*, vol. 9, p. 1563, 2018.

[141] J. Huang, C. Wu, B. Tian, X. Zhou, N. Ma, and Y. Qian, “Myricetin prevents alveolar bone loss in an experimental ovariec-tomized mouse model of periodontitis,” *Int J Mol Sci*, vol. 17, no. 3, p. 422, 2016.

[142] A. Lektemur Alpan, A. Kizildag, M. Ozdede, N. C. Karakan, and O. Ozmen, “The effects of taxifolin on alveolar bone in experimental periodontitis in rats,” *Arch Oral Biol*, vol. 117, article 104823, 2020.

[143] Y. Ishimi, C. Miyaura, M. Ohmura et al., “Selective effects of genistein, a soybean isoflavone, on B-lymphopoiesis and bone loss caused by estrogen deficiency,” *Endocrinology*, vol. 140, no. 4, pp. 1893–1900, 1999.

[144] M. Satue, M. Arriero Mdel, M. Monjo, and J. M. Ramis, “Quercitin and taxifolin stimulate osteoblast differentiation in MC3T3-E1 cells and inhibit osteoclastogenesis in RAW 264.7 cells,” *Biochem Pharmacol*, vol. 86, no. 10, pp. 1476–1486, 2013.

[145] T. Tominari, M. Hirata, C. Matsumoto, M. Inada, and C. Miyaura, “Polymethoxy flavonoids, nobiletin and tangere-tin, prevent lipopolysaccharide-induced inflammatory bone loss in an experimental model for periodontitis,” *J Pharmacol Sci*, vol. 119, no. 4, pp. 390–394, 2012.

[146] A. W. Boots, G. R. Haenen, and A. Bast, “Health effects of quercetin: from antioxidant to nutraceutical,” *Eur J Pharmacol*, vol. 585, no. 2-3, pp. 325–337, 2008.

[147] S. C. Bischoff, “Quercetin: potentials in the prevention and therapy of disease,” *Curr Opin Clin Nutr Metab Care*, vol. 11, no. 6, pp. 733–740, 2008.

[148] Y.-D. Min, C.-H. Choi, H. Bark et al., “Quercitin inhibits expression of inflammatory cytokines through attenuation of NF-kappaB and p38 MAPK in HMC-1 human mast cell line,” *Inflamm Res*, vol. 56, no. 5, pp. 210–215, 2007.

[149] T. Kallinich, D. Haßner, T. Niehues et al., “Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement,” *Pediatrics*, vol. 119, no. 2, pp. e474–e483, 2007.

[150] E. Ben-Chetrit, J. M. Scherrmann, E. Zylber-Katz, and M. Levy, “Colchicine disposition in patients with familial
Mediterranean fever with renal impairment,” *J Rheumatol*, vol. 21, no. 4, pp. 710–713, 1994.

[151] C. A. Aral, K. Aral, A. Yay, O. Ozcoban, A. Berdeli, and R. Saraymen, “Effects of colchicine on gingival inflammation, apoptosis, and alveolar bone loss in experimental periodontitis,” *J Periodontol*, vol. 89, no. 5, pp. 577–585, 2018.

[152] C. N. Serhan, “Pro-resolving lipid mediators are leads for resolution physiology,” *Nature*, vol. 510, no. 7503, pp. 92–101, 2014.

[153] C. N. Serhan, N. Chiang, and T. E. Van Dyke, “Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators,” *Nat Rev Immunol*, vol. 8, no. 5, pp. 349–361, 2008.

[154] R. S. De Molon, R. M. Thurlings, B. Walgreen et al., “Factors produced by microorganisms,” in *Periodontal inflammation physiology*, vol. 197, no. 7, pp. 2796–2806, 2016.

[155] M. Wan, C. Godson, P. J. Guiy, B. Agerberth, and J. Z. Haeggstrom, “Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1,” *FASEB J*, vol. 25, no. 5, pp. 1697–1705, 2011.

[156] S. Muruganandan, A. A. Roman, and C. J. Sinal, “Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells,” *J Bone Miner Res*, vol. 25, no. 2, pp. 222–234, 2010.

[157] Z. Z. Xu, L. Zhang, T. Liu et al., “Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions,” *Nat Med*, vol. 16, no. 5, pp. 592–597, 2010, 591p following 597.

[158] H. Hasturk, A. Kantarci, E. Goguet-Surmenian et al., “Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo,” *J Immunol*, vol. 179, no. 10, pp. 7021–7029, 2007.

[159] C.-T. Lee, R. Teles, A. Kantarci et al., “Resolvin E1 reverses experimental periodontitis and dysbiosis,” *J Immunol*, vol. 197, no. 7, pp. 2796–2806, 2016.

[160] H. Hasturk, R. Abdallah, A. Kantarci et al., “Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis,” *Arterioscler Thromb Vasc Biol*, vol. 35, no. 5, pp. 1123–1133, 2015.

[161] K. El Kholy, M. Freire, T. Chen, and T. E. Van Dyke, “Resolvin E1 promotes bone preservation under inflammatory conditions,” *Front Immunol*, vol. 9, p. 1300, 2018.

[162] T. E. Van Dyke, “Shifting the paradigm from inhibitors of inflammation to resolvers of inflammation in periodontitis,” *J Periodontol*, vol. 91, Suppl 1, pp. 519–525, 2020.

[163] D. M. Lilly and R. H. Stillwell, “Probiotics: growth-promoting factors produced by microorganisms,” *Science*, vol. 147, no. 3659, pp. 747–748, 1965.

[164] H. Shimauchi, G. Mayanagi, S. Nakaya et al., “Improvement of periodontal condition by probiotics with Lactobacillus salivarius WB21: a randomized, double-blind, placebo-controlled study,” *J Clin Periodontol*, vol. 35, no. 10, pp. 897–905, 2008.

[165] I. Stamatova and J. H. Meurman, “Probiotics and periodontal disease,” *Periodontol*, vol. 51, pp. 141–151, 2000.

[166] R. M. Moraes, C. M. Lescura, N. V. M. Milhan, J. L. Ribeiro, F. A. Silva, and A. L. Anbinder, “Live and heat-killed Lactobacillus reuteri reduce alveolar bone loss on induced periodontitis in rats,” *Arch Oral Biol*, vol. 119, article 104894, 2020.

[167] R. S. Cardoso, M. R. Messora, P. H. F. Silva et al., “Effects of *Bifidobacterium animalis* subsp. lactis HN019 on ligature-induced periodontitis in rats with experimental rheumatoid arthritis,” *Benef Microbes*, vol. 11, no. 1, pp. 33–46, 2020.

[168] M. S. Ricoldi, F. A. Furlaneto, L. F. Oliveira et al., “Effects of the probiotic *Bifidobacterium animalis* subsp. lactis on the non-surgical treatment of periodontitis. A histomorphometric, microtomographic and immunohistochemical study in rats,” *PLoS One*, vol. 12, no. 6, article e0179946, 2017.

[169] L. F. Oliveira, S. L. Salvador, P. H. Silva et al., “Benefits of *Bifidobacterium animalis* subsp. lactis probiotic in experimental periodontitis,” *J Periodontol*, vol. 88, no. 2, pp. 197–208, 2017.

[170] S. M. Gatej, V. Marino, R. Bright et al., “Probiotic Lactobacillus rhamnosus GG prevents alveolar bone loss in a mouse model of experimental periodontitis,” *J Clin Periodontol*, vol. 45, no. 2, pp. 204–212, 2018.

[171] T. Maekawa and G. Hajishengallis, “Topical treatment with probiotic Lactobacillus brevis CD2 inhibits experimental periodontal inflammation and bone loss,” *J Periodontal Res*, vol. 49, no. 6, pp. 785–791, 2014.

[172] R. Kobayashi, T. Kobayashi, F. Sakai, T. Hosoya, M. Yamamoto, and T. Kurita-Ochiai, “Oral administration of Lactobacillus gasseri SBT2055 is effective in preventing Porphyromonas gingivalis-accelerated periodontal disease,” *Sci Rep*, vol. 7, no. 1, p. 545, 2017.

[173] Y. L. A. S. Levi, G. S. Novaes, R. B. Dias et al., “Effects of the probiotic mannan oligosaccharide on the experimental periodontitis in rats,” *J Clin Periodontol*, vol. 45, no. 9, pp. 1078–1089, 2018.

[174] V. Slomka, E. Hernandez-Sanabria, E. R. Herrero et al., “Nutritional stimulation of commensal oral bacteria suppresses pathogens: the probiotic concept,” *J Clin Periodontol*, vol. 44, no. 4, pp. 344–352, 2017.

[175] T. Tomofuji, D. Ekuni, T. Sanbe et al., “Effects of vitamin C intake on gingival oxidative stress in rat periodontitis,” *Free Radic Biol Med*, vol. 46, no. 2, pp. 163–168, 2009.

[176] D. E. Clark, J. M. Navia, L. R. Manson-Hing, and H. E. Duncan, “Evaluation of alveolar bone in relation to nutritional status during pregnancy,” *J Dent Res*, vol. 69, no. 3, pp. 890–895, 1990.

[177] N. Amaraseka, H. Ogawa, A. Yoshihara, N. Hanada, and H. Miyazaki, “Serum vitamin C-periodontal relationship in community-dwelling elderly Japanese,” *J Clin Periodontol*, vol. 32, no. 1, pp. 93–97, 2005.

[178] S. Akman, V. Canakci, A. Kara, U. Tozoglu, T. Arabaci, and I. M. Dagsu, “Therapeutic effects of alpha lipolic acid and vitamin C on alveolar bone resorption after experimental periodontitis in rats: a biochemical, histochemical, and stereologic study,” *J Periodontol*, vol. 84, no. 5, pp. 666–674, 2013.

[179] A. Akpinar, N. C. Karakan, A. L. Alpan, S. S. A. Dogan, F. Goze, and O. Poyraz, “Comparative effects of riboflavin, nicotinamide and folic acid on alveolar bone loss: a morphometric and histopathologic study in rats,” *Srp Arh Celok Lek*, vol. 114, no. 5–6, pp. 273–279, 2016.

[180] R. F. Neiva, K. Al-Shammari, F. H. Nociti Jr., S. Soehren, and H. L. Wang, “Effects of vitamin-B complex supplementation on periodontal wound healing,” *J Periodontol*, vol. 76, no. 7, pp. 1084–1091, 2005.

[181] B. Willershausen, A. Ross, M. Forsch, I. Willershausen, P. Mohaupt, and A. Callaway, “The influence of
micronutrients on oral and general health,” *Eur J Med Res*, vol. 16, no. 11, pp. 514–518, 2011.

[182] G. Zong, B. Holtfreter, A. E. Scott et al., “Serum vitamin B12 is inversely associated with periodontal progression and risk of tooth loss: a prospective cohort study,” *J Clin Periodontol*, vol. 43, no. 1, pp. 2–9, 2016.

[183] A. Mohammadi, L. Omrani, L. R. Omrani et al., “Protective effect of folic acid on cyclosporine-induced bone loss in rats,” *Transpl Int*, vol. 25, no. 1, pp. 127–133, 2012.

[184] J. Lee, J.-C. Park, U.-W. Jung et al., “Improvement in periodontal healing after periodontal surgery supported by nutritional supplement drinks,” *J Periodontal Implant Sci*, vol. 44, no. 3, pp. 109–117, 2014.

[185] E. Toubi and Y. Shoenfeld, “The role of vitamin D in regulating immune responses,” *Isr Med Assoc J*, vol. 12, no. 3, pp. 174-175, 2010.

[186] J. Tang, R. U. Zhou, D. Luger et al., “Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response,” *J Immunol*, vol. 182, no. 8, pp. 4624–4632, 2009.

[187] Y. Arnson, H. Amital, and Y. Shoenfeld, “Vitamin D and autoimmunity: new aetiological and therapeutic considerations,” *Ann Rheum Dis*, vol. 66, no. 9, pp. 1137–1142, 2007.

[188] K. Aral, B. A. Alkan, R. Saraymen, A. Yay, A. Sen, and G. O. Onder, “Therapeutic effects of systemic vitamin k2 and vitamin d3 on gingival inflammation and alveolar bone in rats with experimentally induced periodontitis,” *J Periodontol*, vol. 86, no. 5, pp. 666–673, 2015.